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Abstract
	
  
Right ventricular dysfunction is the most frequent cause of death in patients with
pulmonary arterial hypertension. Although abnormal energy substrate use has been
implicated in the development of chronic left heart failure, data describing such
metabolic remodeling in failing right ventricular tissue remain incomplete. In the present
dissertation we sought to characterize metabolic gene expression changes and
mitochondrial dysfunction in functional and dysfunctional RV hypertrophy.
Two different rat models of RV hypertrophy were studied. The model of right ventricular
failure (SU5416/hypoxia) exhibited a significantly decreased gene expression of
peroxisome proliferator-activated receptor- coactivator-1α, peroxisome proliferatoractivated receptor-α and estrogen-related receptor-α. The expression of multiple
peroxisome proliferator-activated receptor- coactivator-1α target genes required for fatty
acid oxidation was similarly decreased. Decreased peroxisome proliferator-activated
receptor- coactivator-1α expression was also associated with a net loss of mitochondrial
protein and oxidative capacity. Reduced mitochondrial number was associated with a
downregulation of transcription factor A, mitochondrial, and other genes required for
mitochondrial biogenesis. Electron microscopy demonstrated that, in right ventricular
failure tissue, mitochondria had abnormal shape and size. Lastly, respirometric analysis
demonstrated that mitochondria isolated from right ventricular failure tissue had a
significantly reduced ADP- stimulated (state 3) rate for complex I. Conversely, functional
right ventricular hypertrophy in the pulmonary artery banding model showed normal
expression of peroxisome proliferator-activated receptor- coactivator-1α, whereas the
expression of fatty acid oxidation genes was either preserved or unregulated. Moreover,
	
  

v	
  

pulmonary artery banding-right ventricular tissue exhibited preserved transcription factor
A mitochondrial expression and mitochondrial respiration despite elevated right
ventricular pressure-overload. We conclude that right ventricular dysfunction, but not
functional right ventricular hypertrophy in rats, demonstrates a gene expression profile
compatible with a multilevel impairment of fatty acid metabolism and significant
mitochondrial dysfunction, partially independent of chronic pressure-overload.
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Chapter 1: General introduction to pulmonary hypertension and right ventricular
failure. Rationale and outline of the thesis

Segments of this chapter have been previously published in:
Voelkel NF, Gomez-Arroyo J, et al. Pathobiology of pulmonary arterial hypertension
and right ventricular failure. Eur Respir J. 2012 Dec;40(6):1555–1565.
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CHAPTER 1

“Further research is essential in order that the etiology of the disease to be discovered.
Once the mechanism is known, perhaps it can be arrested or reversed […] Thus, the
ultimate hope is for a discovery of the basic mechanisms which now are unknown”

N.F Voelkel and J.T. Reeves, 1979

1. 1 General introduction to pulmonary hypertension

Pulmonary hypertension (PH) or high blood pressure in the lung circulation,
occurs in a broad spectrum of diseases of the lung and is defined as an elevation of the
mean pulmonary artery pressure > 25 mmHg(210). Because many lung and systemic
diseases can be associated with pulmonary hypertension, five World Heath Organization
(WHO) meeting groups have worked to categorize PH, since the first classification of the
disease in 1973. Indeed, nowadays the different etiologies of PH have been classified into
5 different groups (Table 1). Understanding the differences between the WHO groups is
critical not only for medical management of the patient with PH but also for the
understanding of the pathogenesis. For the purposes of this dissertation, one could
simplify the causes of PH in two broad groups: 1) Diseases affecting the arterial (precapillary) component of the lung circulation, that is, lung vessels that take deoxygenated
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blood from the right side of the heart (right ventricle) to the lungs and 2) Diseases
affecting the venous (post-capillary) component of the lung circulation, which carries
oxygenated blood to the left ventricle ready to be pumped into the systemic circulation.
In addition to the hemodynamic criterion of a high mean pulmonary artery pressure
(mPAP), the diagnostic definition of WHO Group 1, or pulmonary arterial hypertension
(PAH), adds the criterion of a pulmonary arterial wedge pressure <15 mmHg, which
largely rules out the presence of left heart disease. Although Groups 3, 4 and 5 include
diseases or conditions associated with arterial lung vascular disease, the pathobiology of
the diseases included in these groups is significantly distinct from Group 1. The reader
should be aware that the entire dissertation is focused on Group 1, or pulmonary
arterial hypertension (PAH).
As noted in Table 1, PAH includes conditions that range from congenital heart disease
(different from WHO Group 2 which lists acquired left heart disease), infections, druginduced, hepatopulmonary syndrome, as well as sporadic idiopathic (unknown) and
hereditary idiopathic forms. All forms of PAH are characterized by elevated pulmonary
arterial pressure and elevated blood flow resistance due to a precapillary pulmonary
microangiopathy(243). However, although PAH is a disease originated in the lungs,
patients with the disease die from right ventricular failure(49, 197).
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JACC Vol. 54, No. 1, Suppl S, 2009
June 30, 2009:S43–54
Updated
Pulmonary
Clinical
Hypertension
Classification
(Dana of
Point,Hypertension
2008)
Table
1. Classification
of Pulmonary
Table 2

Updated Clinical Classification of
Pulmonary Hypertension (Dana Point, 2008)

1. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic PAH
1.2. Heritable
1.2.1. BMPR2
1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic
telangiectasia)
1.2.3. Unknown
1.3. Drug- and toxin-induced
1.4. Associated with
1.4.1. Connective tissue diseases
1.4.2. HIV infection
1.4.3. Portal hypertension
1.4.4. Congenital heart diseases
1.4.5. Schistosomiasis
1.4.6. Chronic hemolytic anemia
1.5 Persistent pulmonary hypertension of the newborn
1=. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary
hemangiomatosis (PCH)
2. Pulmonary hypertension owing to left heart disease
2.1. Systolic dysfunction
2.2. Diastolic dysfunction
2.3. Valvular disease
3. Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell
histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid
disorders
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure
on dialysis
Main modifications to the previous Venice classification are in bold.
ALK1 ! activin receptor-like kinase type 1; BMPR2 ! bone morphogenetic protein receptor type
2; HIV ! human immunodeficiency virus.

like kinase 1 or endoglin) and familial cases with or without
identified germline mutations (13,14). The new category of
“heritable PAH” does not mandate genetic testing in
patients with IPAH or in familial cases of PAH. Genetic
as a part of a
	
   testing, when called for, should be performed
4	
  
comprehensive program that includes genetic counseling
and discussion of the risks, benefits, and limitations of such

Classi

of risk factors and the likeliho
been modified. Updated risk
tions for PAH are presente
association is defined as an ep
appetite suppressants in the
epidemiologic studies demonst
a drug and PAH. A “likely”
single-center, case-control stu
tion or a multiple-case series.
with similar mechanisms of ac
or “likely” categories but whic
(e.g., drugs used to treat atten
an “unlikely” association is de
has been studied in epidemiolo
with PAH has not been demo
Aminorex, fenfluramine de
oil represent the only identifi
PAH (3,5). A recent retrospec
cases of PAH associated with f
that this category shares clinic
and genetic features with IPA
mine exposure represents a
without influencing its clinica
The most recent surveillanc
Pulmonary Hypertension in A
1,335 subjects at tertiary PH
1998 and 2001 (17). This stud
fenfluramine and dexfenfluram
ment of PAH. The average mo
did not change during the
conducted after fenfluramine
withdrawn from the U.S. mar
St. John’s Wort (odds ratio [O
PH) and over-the-counter a
phenylpropanolamine (OR: 5
also increased the risk of deve
The SOPHIA study exam
nonselective monoamine reupt
tonin reuptake inhibitors, ant
and found no increased risk
However, a recent case-contro

Updated
and
Associated
Risk Factors
Conditions
for of PAH
Table 3

Updated Risk Factors

Table 1. Updated clinical classification of pulmonary arterial hypertension groups
according the World Health Organization. ALK1 = activin receptor-like kinase type 1;
BMPR2 = bone morphogenetic protein receptor type
2; HIV = human immunodeficiency virus. Reproduced from Simonneau G, et al. Updated
clinical classification of pulmonary hypertension. Journal of the American College of
Cardiology. 2009 Jun 30;54(1 Suppl):S43–54. Copyright 2009, with permission from
Elsevier.
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1.2 Brief historical and current perspective of the disease

Idiopathic pulmonary arterial hypertension (IPAH), formerly known as primary
pulmonary hypertension, is the best-characterized form of PH. The term idiopathic refers
to a disease of unexplained etiology and therefore patients diagnosed with IPAH do not
have a coexisting cardiac or pulmonary disease(209). In other words, the diagnosis of
IPAH remains a ‘diagnosis of exclusion’. The disease was first described in 1891 by
Romberg and later on by Ayerza in 1901 who reported patients with heart failure and
severe cyanosis (‘negros cardiacos’) associated with ‘brochopulmonary sclerosis’(247).
The first systematic description was not reported until 1935 by Brenner(29) and did not
become a clinical entity until 1951, when Dresdale and collaborators described its clinical
and hemodynamic features(247). All forms of PAH, including IPAH, are characterized
by a common histopathological feature: the presence of plexiform-like lesions (Figure 1)
(243), hence the former name of ‘unexplained plexogenic pulmonary arteriopathy’. This
concept was further developed by Heath and Edwards who, in 1958, defined the
structural vascular changes in the lungs of patients with PAH(247). After first
anorexigen-induced (aminorex fumarate) epidemic of pulmonary hypertension in Europe
in 1967-1970, the husband and wife Wagenvoort and Wagenvoort reported the largest
series of autopsied patients providing the structural criteria for the diagnosis of PAH and
its separation from other forms of pulmonary hypertension, which now are included in
WHO Groups 2-5.
It should be noted that unlike other diseases, including infectious diseases, cancer or
even pulmonary or cardiovascular (myocardial infarction, atherosclerosis, stroke)
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diseases, PAH was a relatively unrecognized medical condition until rather recently.
As reviewed by Voelkel and Reeves, until the year 1979(241), researchers and clinicians
knew that PAH was a lung vascular disease predominantly affecting women (5:1), that it
could affect patients of any age but the highest incidence occurred between the ages of 25
and 29 years and perhaps, most importantly, it was well recognized that the disease had
no cure or treatment and therefore, upon diagnosis, the prognosis of the patient was
dismal. Indeed, the mean survival time of patients was 2 to 3 years after diagnosis(247).
Because of the heterogeneity of the data collected from rather small patient cohorts, in
1981, the Patient Registry for the Characterization of Primary Pulmonary Hypertension
was established by the National Heart, Lung, and Blood Institute of the National
Institutes of Health. This was the first prospective collection of data based on
standardized protocols, which included a initial diagnostic catheterization(49). A total of
194 patients from 32 medical centers in the United States were recruited and followed-up
in order to define survival patterns based on hemodynamic parameters. The data of this
registry provided for the first time a solid hemodynamic description of IPAH and
demonstrated that survival strongly correlated with the function of RV.
Five World Symposia on pulmonary hypertension have taken place in the past two
decades (the last in 2013) and scientists as well as clinicians have thoroughly categorized
the diverse forms of PH and have consolidated the data produced in many laboratories
and clinical centers around the world. Today, almost a quarter of a century after first NIH
national registry, the data from the Registry to Evaluate Early and Long Term PAH
Disease Management (REVEAL), the largest registry in the United States, indicate that
the phenotype of idiopathic PAH, has significantly changed. Today, up to 79% of patients
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are obese women close to menopausal age (69). However, there is an apparent
discrepancy in the PAH phenotype between US and European registries(62, 105, 169),
suggesting, perhaps, currently unidentified regional environmental factors that could
contribute to the development and progression of the disease. Furthermore, PAH is no
longer an orphan disease(102). Unlike 20 years ago, three classes of drugs have been
developed and an increasing number of patients are being treated with a single drug or a
combination therapy (22, 104). The advent of PAH-specific therapies has improved the
survival of PAH patients in comparison the survival published in historic registries.
However, in spite of treatment, the mortality remains unacceptably high, as the
survival for incident patients continues to be as low as 54.9% at 3 years after diagnosis
(95% CI, 41.8 to 68.0)(107). In other words, although new therapies improve
survival, PAH remains an incurable and rapidly progressive disease. Indeed,
although the structural changes that explain the “fixed pulmonary hypertension” of PAH
patients have been described in recent decades (13, 181, 250) and new pathobiological
concepts of PAH have been described(199, 232), current PAH-specific drugs are
predominantly vasodilators(106) and do not stop the progression of the disease(213).
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and speculating further, abnormal endothelial cells with a hyperproliferative potential could be released from the complex
vascular lesions and recirculate into the lung where they are
then trapped within partially obliterated lung vessels. The proliferating endothelial cells of the complex vascular lesions appear to proceed ‘‘via a process formally analogous to Darwinian
evolution, in which a succession of genetic changes, each conferring one or another growth advantage, leads to the progressive
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esions demonstrates the expression pattern of several markers of malignancy. (A) Expression of p16 in the central
proximal portions of bifurcating vessels). (B) Highly expressed b-catenin. (C) Luminal endothelial cell expression of
(MDRP) in a plexiform lesion. (D) Increased expression of survivin in central portion of plexiform lesion. (E) Dense
r (CXCR)-4 in a plexiform lesion. (F) Expression of epithelial growth factor receptor (EGFR)-3 in a plexiform lesion.
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Figure 1. Comparison between a plexiform-like lesion from the lung of a patient
with pulmonary arterial hypertension and a renal glomerulus. Micrographs obtained
with a light-microscope illustrate the similarities between a classic plexiform-like lesion
in a patient with pulmonary arterial hypertension (A) and a normal renal glomerulus (B).
Complex vascular remodeling, as illustrated in panel A, is not present in the lung under
normal conditions. Panel A figure was reprinted with permission of the American
Thoracic Society. Copyright © 2013 American Thoracic Society from Rai PR, et al. The
cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med.
2008,15;178(6):558–564 (Ref. (178, 183)).
Official Journal of the American Thoracic Society. Panel B was reproduced from Pontén
F et al. A global view of protein expression in human cells, tissues, and organs. Mol Syst
Biol. 2009 5:337 (Ref (49, 178)).
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1.3 Outline of the dissertation, justification and general hypothesis
The entire dissertation consists of seven chapters. CHAPTER 2 is a compendium of the
current literature discussing the pathobiology of PAH, which has significantly evolved
from the early concepts proposed by many experts two decades ago. Although the data
derived from cell-based models and human samples have provided the basis for the
generation of novel hypotheses about the genesis of the disease, many questions remain
unanswered. Because, animal models of the disease are fundamental not only to the better
understanding of the disease but also for pre-clinical testing of new pharmacotherapies, in
CHAPTER 4 we broadly discuss the existing literature, as well as our own data,
regarding the current animal models utilized to study PAH. Given that an ‘ideal’ animal
model of pulmonary is not yet available, we sought to characterize the problems and
prospects of the most prevalent animal model of pulmonary hypertension, the
monocrotaline-injury and the SU5416/hypoxia rat models, as well as several transgenic
mouse models reported in the literature and studied in our laboratory. This chapter is of
particular importance to the reader because it provides the necessary rationale for
the use of the SU5416/hypoxia rat model of PH, the principal animal model used for
the studies described in this dissertation.
The direct consequence of the lung vascular remodeling present in patients with PAH are
restricted blood flow and increased vascular resistance, all of which translates into
increased right ventricular afterload (Figure 2)(246). Although, right ventricular failure
(RVF) is the most frequent cause of death of patient with PAH(22, 49, 104, 197), the
interactions between the remodelled lung circulation and the right ventricle (RV) are only
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Figure 2.
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Figure 2. Pulmonary Arterial Hypertension: Natural history of disease. Schematic
representation of the natural history of pulmonary arterial hypertension. Pulmonary
vascular remodeling will be directly translated into increased blood flow resistance and
therefore, increased pulmonary pressure. Right ventricular dysfunction and failure will be
the direct consequence of increased pulmonary pressure (also known as RV after load).
Image of lung vascular lesion was reproduced from Rai PR, et al. The cancer paradigm
of severe pulmonary arterial hypertension. Am J Respir Crit Care Med.
2008,15;178(6):558–564 (Ref. (183)).

	
  

13	
  

partially understood(246). Furthermore, a detailed description of the cellular and
molecular mechanistic elements that explain RV failure (“RV failure program”) is
incomplete.
Given the prognostic importance of RV dysfunction/failure in PAH, understanding
the mechanisms underlying the transition from adaptive (functional) to maladaptive
(dysfunctional) right ventricular hypertrophy is critical, particularly if any to these
mechanisms can be prevented or reversed.

CHAPTER 3 discusses pertinent data highlighting unmet needs based on our current
concepts of the pathobiology of RVF and provides an overall justification for the study of
RV failure mechanisms. Chapter 3 also provides the basic cardiac physiology concepts
that underlie the experimental approaches taken. As part of a preliminary project, we
studied explanted hearts obtained from autopsy material of two different groups with
pulmonary arterial hypertension and analyzed the differences in RV hypertrophy. These
data are presented as part of Chapter 3.
Indeed, our knowledge of the pathobiology and pathophysiology of RVF has evolved
from the state available two decades ago. New concepts such as fibrosis, capillary
rarefaction, cardiac hibernation and cardiomyocyte apoptosis now complement the
classical theory of load-dependent, wall stress-induced RV dysfunction. Because left
ventricular failure, in the setting of chronic pressure overload (i.e systemic hypertension)
is characterized by changes in energy substrate utilization and abnormal mitochondrial
biology, we sought to characterize the changes in mitochondrial energy metabolism
during RV failure.
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We hypothesized that maladaptive RV hypertrophy, but not functional/adaptive RV
hypertrophy would be characterized by abnormal cardiac metabolism and
mitochondrial dysfunction.

To begin to address our research question, we utilized 2 different animal models of
chronic RV pressure overload, the SU5416/hypoxia and the pulmonary artery banding
models. CHAPTER 5 provides a detailed description of the methodology used
throughout the studies and the results are presented in CHAPTER 6. Lastly, CHAPTER
7 includes published and unpublished data regarding additional therapeutic strategies
utilized to reverse the metabolic changes and RV failure described in Chapter 6.
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Chapter 2: Pathobiology of Pulmonary Arterial Hypertension

Segments of this chapter have been previously published in:
Voelkel NF, Gomez-Arroyo J, et al. Pathobiology of pulmonary arterial hypertension
and right ventricular failure. Eur Respir J. 2012 Dec;40(6):1555–1565.
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CHAPTER 2

“Mexiform lesion” - © Jose Gomez-Arroyo

2.1 Introduction
As briefly stated in Chapter 1, our knowledge of the pathobiology of PAH has
significantly changed from what was initially proposed two decades ago(243). Early
hypotheses derived from autopsy studies and animal models of hypoxia-induced
pulmonary hypertension postulated that 1) vasoconstriction, 2) vascular remodeling and
3) thrombosis in situ were the main components contributing to the development of the
disease. Indeed these three components became the main targets for the therapies
designed to treat patients with PAH(106). However, whereas it is true that
vasoconstriction plays a role in the disease, that a small group of patients have a highly
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vasorreactive (perhaps, completely different) form of PAH, and that thrombosis is
frequently observed in small vessels(71), the use of vasodilator therapy and
anticoagulants has not had a great impact on disease progression(72, 213). Therefore,
new hypotheses based on human samples, cell-based and animal models have been
developed. Although some of these concepts have been previously considered as part of
the disease (Figure 3), mechanistic studies addressing the role of genetics, epigenetics
and immune dysregulation in the pathogenesis of the PAH had not been reported until
rather recently. This chapter intends to put in perspective the newly postulated
pathobiological concepts of PAH, which reflect the progress made in the understanding
of this complex pulmonary vascular disease.

2.2 Genetic influences and epigenetics in PAH
The pathogenesis of PAH is based on more than one hits, and genetic factors conferring a
predisposition for the development or progression of severe PAH may be required as one
of the hits (Figure 4)(136, 157, 175). Mutations of the Bone Morphogenic Type II
Receptor (BMPR2) gene, a member of the transforming growth factor (TGF-β)
superfamily, were first described in patients with familial/hereditary PAH (HPAH)(157).
Although BMPR2 mutations in HPAH have a high prevalence (70%), limited numbers of
patients with IPAH have mutations(136), and only 20% of the carriers ever develop PAH
during their lifetime(136). BMPR2 mutation carriers at the time of PAH-diagnosis are
younger (77, 175) and less likely have a vasoreactive component(59). A large number of
mutations have
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Figure 3. Early postulated hypothesis of the pathogenesis of pulmonary arterial
hypertension.
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Figure 3. Data derived from the analysis of human samples and from the study of animal
models of hypoxic pulmonary hypertension lead to the generation of early hypotheses
that considered vasoconstriction a central component of the pathogenesis of pulmonary
hypertension. Copyright 1979. Reproduced with permission of the publisher. The image
was obtained from Voelkel N, Reeves JT. Chapter 10: Primary Pulmonary Hypertension.
In: Moser KM, editor. Pulmonary Vascular Diseases. New York: Marcel Dekker, Inc;
1979.
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been reported and the majority translate into a loss of function (137) or reduced BMPR2
expression(14). It has been reported that the disease appears to be more severe when
patients carry a truncating BMPR2 mutation(15) however, this appears not to be the case
in the French patients (77). Mechanistic studies indicate that BMPR2 mutations are
permissive but not necessary for the development of severe PAH. BMPR2 may be one of
the guardians of lung vessel homeostasis, as gene knockout and silencing experiments
have clearly demonstrated that both apoptosis and cell proliferation of pulmonary
vascular smooth muscle and endothelial cells are controlled by BMPR2(150). Intact
BMPR2 signaling may be necessary for the execution of a normal lung vascular woundhealing program, preventing apoptosis-induced compensatory cell proliferation. BMPR2
loss makes cells more susceptible to apoptosis(226), however, vascular cell-apoptosis
alone, is insufficient for angioproliferation to occur. BMPR2 signaling appears to define
the cellular identity during reparative responses(230). BMP signaling is regulated at
many different levels and each level could potentially contribute to abnormal BMPR2
function, without necessarily involving a mutation in the BMPR2 gene(150). For
example, mutations in the type I TGF-β receptor, ALK-1(76, 218, 229), have been
observed in patients with severe PAH occurring in families with hereditary hemorrhagic
telangiectasia. Moreover, although infrequent, mutations in the BMPR2-downstream
mediators, the smad proteins, have also been described in PAH patients(155). In the
aggregate the data indicate that BMP/TGF-β signalling plays an important role in the
maintenance of the normal lung arteriolar structure.
Epigenetic mechanisms influence gene expression via modifications of the chromatin,
histones and regulatory micro RNAs(95). At present, there is no firm evidence that PAH

	
  

21	
  

N.F. VOELKEL ET AL.

REVIEW: PATHOBIOLOGY OF PAH

Figure 4. Hallmarks of severe angioproliferative pulmonary arterial hypertension.
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FIGURE 1.

Hallmarks of severe angioproliferative pulmonary arterial hypertension. Genetic determinants, epigenetic factors and other conditions synergise and result in

the injury and apoptosis of pulmonary arteriolar endothelial cells. Endothelial cell apoptosis triggers compensatory proliferation of phenotypically abnormal endothelial cells.
Apoptosis may also be the initiating event, activating the bone marrow to release precursor and stem cells and eliciting a local immune response of the vascular wall. The end
result is the complex vascular lesion, the plexiform lesion. These complex lesions obliterate the lumen of small arteries, predominantly localised to vessel bifurcations. The
mature lesions are composed of endothelial cells (dark purple), smooth muscle cells (yellow), apoptotic cells (purple) and phenotypically altered apoptosis-resistant
endothelial cells (red). These cells, together inflammatory cells, populate a microenvironment of exuberant cell growth. BMPR2: bone morphogenic type II receptor; ALK-1:
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activin A receptor type-II like-1; HSC: hematopoietic stem cell; EPC: endothelial progenitor cell.

c

Figure 4. Genetic determinants, epigenetic factors and other conditions synergise and
result in the injury and apoptosis of pulmonary arteriolar endothelial cells. Endothelial
cell apoptosis triggers compensatory proliferation of phenotypically abnormal endothelial
cells. Apoptosis may also be the initiating event, activating the bone marrow to release
precursor and stem cells and eliciting a local immune response of the vascular wall. The
end result is the complex vascular lesion, the plexiform lesion. These complex lesions
obliterate the lumen of small arteries, predominantly localised to vessel bifurcations. The
mature lesions are composed of endothelial cells (dark purple), smooth muscle cells
(yellow), apoptotic cells (purple) and phenotypically altered apoptosis-resistant
endothelial cells (red). These cells, together inflammatory cells, populate a
microenvironment of exuberant cell growth. BMPR2: bone morphogenic type II receptor;
ALK-1: activin A receptor type-II like-1; HSC: hematopoietic stem cell; EPC:
endothelial progenitor cell. Copyright 2012. Reproduced with permission of the publisher
from Voelkel NF et al, et al. Pathobiology of pulmonary arterial hypertension and right
ventricular failure. Eur Respir J. 2012 Dec;40(6):1555–1565.
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has an epigenetic component(119). Downregulation of BMPR2 expression has been
explained by activation of a STAT3/miRNA-17-92 microRNA axis in normal human
lung endothelial cells after interleukin-6 exposure(31). Interestingly, mice overexpressing
IL-6 develop severe pulmonary hypertension(214) and, unlike other PH mice models ,
also develop angioobliterative vascular remodelling and robust RV hypertrophy(82).
Overexpression of miR-17 also increases proliferation of human pulmonary artery
smooth muscle cells and inhibition with an specific miR-17 antagomir ameliorated PH in
two experimental models(180). Another microRNA, miRNA-204, has been found
downregulated in pulmonary artery smooth muscle cells isolated from patients with
PAH(44). Upregulation of miR204 seems to induce an apoptosis-resistant phenotype in
smooth muscle cells.
2.3 The paradigm shift: From vasoconstriction to cell growth.
Terms like “cell phenotype switch,” “apoptosis-resistance” and “angiogenic niche” have
introduced a new vocabulary which can be used to explain the pathobiology of
PAH(183). The early pioneers of PH research focused their attention on hypoxic
vasoconstriction(254), and because the arachidonic acid-derived prostacyclin is a
powerful inhibitor of hypoxic pulmonary vasoconstriction(242), it was thus intuitive to
establish prostacyclin infusion as the first treatment for severe PAH(17). Since then, rapid
progress has been made. Our knowledge of the cellular and molecular components
involved in the pathobiology of PAH has expanded and these new insights are likely to
change our future approach to the treatment of PAH. We now regard the plexiform
pulmonary vascular lesions as a product of an angioproliferative process leading to
vascular occlusion (angioobliteration)(183, 232) and we appreciate that these lesions are
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composed of a multitude of cell types, among them, actively dividing and phenotypically
abnormal apoptosis-resistant endothelial cells with a monoclonal origin(129), progenitor
cells(148) and immune cells(40, 171, 172). Immunohistochemistry, using antibodies
directed against cell surface epitopes and nuclear markers of cell activation, identifies
different cell phenotypes with their expressed genes and proteins(183). Hallmarks of
cancer in angioproliferative PAH have been described, in particular angiogenesis(232),
metabolic changes(262) and apoptosis-resistant cells(193). Based also on the therapy
refractoriness of PAH, a hypothesis of “quasi-malignancy” has been proposed(183):
apoptosis may be the initiating event followed by the selection of proliferating
apoptosis-resistant cells –some of which may be stem cells (Figure 4). PAH plexiform
lesions also show decreased expression of the tumor-suppressor protein peroxisome
proliferator activated receptor (PPAR) gamma(9), while exhibiting increased expression
of β-catenin, CXCR4 (a receptor that mediates metastatic cell homing), and survivin,
among other(183). Survivin, an inhibitor of apoptosis, is expressed in essentially all
cancers, and cultured cells isolated from the lungs of PAH patients exhibit a markedly
increased expression of survivin. Moreover, experimental gene therapy targeting this
protein suppresses proliferation and ameliorates PAH in rats(141). Another hallmark of
cancer is the metabolic switch towards glycolysis (Warburg effect, perhaps as a defense
against oxidative damage). Pulmonary arterial endothelial cells from IPAH patients
cultured in vitro, demonstrate reduced oxygen consumption, reduced mitochondrial
respiration and increased glycolytic metabolism(262).
The “quasi-malignancy” disease model also accommodates the concept of a cancer stem
cell/angiogenic niche(183). Precursor cells can be transported into the pulmonary
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vascular adventitia via vasa vasorum(263), stem cells can divide and migrate from a
niche at the media-adventitia border zone(61) and pulmonary microvascular endothelial
cell stem cells of small arteries(8) may proliferate to the point of lumen obliteration. It is
presently unclear whether stem- and precursor cells are friends or foes. For example,
autologous endothelial progenitor cells transplantation therapy for PAH has reported
positive results(252). However, this early trial has been criticized(228) because the cells
utilized for the clinical trial were not “true” progenitors. Conversely, anti c-Kit (a stem
cell marker) treatment for PAH with the tyrosine kinase inhibitor imatinib mesylate, has
demonstrated anectodal positive results(75). Stem cell-based gene therapy is currently
being investigated in a clinical trial (NCT00469027).
Growth factors and receptor tyrosine kinases
Many potent cell growth factors are overexpressed in IPAH vascular lesions, and it is
likely that these growth factors and their receptor tyrosine kinases contribute to cell
growth and vessel obliteration. The Platelet Derived Growth Factor (PDGF) has been
extensively studied in PAH(173), and it has been shown that PDGF can induce the
proliferation and migration of SMCs and fibroblasts. PDGF has been proposed as a key
mediator in the progression of several fibroproliferative disorders. It was postulated that
PDGF receptor blockers could reverse PAH, based on the case report of a patient with
end-stage IPAH, treated with imatinib mesylate. Subsequently, a clinical safety trial
evaluating imatinib mesylate as a treatment of advanced forms of PAH was
performed(74). The data showed a significant decrease in pulmonary vascular resistance
(PVR) and a moderate increase in cardiac output, but no significant change in pulmonary
artery pressures, leading to the conclusion that imatinib mesylate may have a limited role
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in the treatment of IPAH patients. Other tyrosine kinase inhibitors for PAH are being
studied(78, 160). It is important that the tyrosine kinase inhibitors imatinib, sorafenib and
nilotinib were shown in animal studies to be acute pulmonary vasodilators(2). However,
the vasodilator effect in clinical studies of PAH was not prominent. This is an example,
that identifying highly specific molecular targets in PAH animal models that do not
reproduce the salient features of human PAH, may be misleading and the drug effect may
be lost in translation(81, 82). Paradoxically, dasatinib, a multi-tyrosine kinase inhibitor,
has been associated with the development of PAH(94, 147).
2.4 Inflammation and Immune Response
The association of autoimmune disorders with PAH and the presence of antinuclear and
antiphospholipid antibodies in the serum of patients with IPAH has been appreciated for
many years(158). There is more evidence that lymphoid neogenesis occurs in IPAH;
macrophages, mast cells, T- and B- lymphocytes, plasma cells and anti-endothelial cell
antibodies are present in and around the complex pulmonary vascular lesions in IPAH
patients(171, 232). Serum levels of IL-1 and IL-6 are high in IPAH patients(103), and
serum IL-6 levels negatively predict patient survival(211). However, whether
inflammation and aberrant immune responses in IPAH are cause or consequence remains
unknown. Likely PH occurs when an inflammatory pulmonary arteriolar injury is not
resolved by (normally) protective, innate anti-inflammatory mechanisms. Regulatory Tcells (Tregs) control not only other T-cells but also regulate monocytes, macrophages,
dendritic cells, natural killer cells and B-cells(192), and recent evidence suggests that
decreased Treg cell number or function may favour the development of PH(221). For
example, conditions associated with PAH, such as HIV, systemic sclerosis, systemic
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lupus erythematosus, Hashimoto’s thyroiditis, Sjogren’s Syndrome and the
antiphospholipid syndrome are characterized by abnormal CD4+ T-cell number and
function(28, 45, 139, 167, 182, 212). At the experimental level, athymic rats, lacking Tcells, develop pronounced PH after vascular injury with a vascular endothelial growth
factor receptor blocker. The lungs in these animals are populated by infiltrating
macrophages, mast cells and B cells, similar to human PAH lesions(221, 224). Most
importantly, PH is prevented by immune reconstitution of Tregs prior to the induction of
vascular injury(221). All together, it is a possibility that aberrant Treg-cell function in the
face of vascular injury can result in heightened innate and adaptive immune responses
that could initiate and/or propagate the development of PH (120)(Figure 5). Despite the
increasing evidence suggesting a role for immune deregulation in PAH, there is only
limited anecdotal evidence suggesting that PH associated with connective tissue disorders
–such as systemic lupus erthyematosis and systemic sclerosis or viral infections, such as
human herpes virus-8 – can respond to gluococorticoids or targeted B cell depletion(93,
116). Sanchez et al(196) and Jais et al(111) reported on treatment of patients with mixed
connective tissue disease - or systemic lupus erythematosus – associated PH, where
corticosteroid and cyclophosphamide has been used as first-line drugs. The effectiveness
of B cell depletion is currently being put to test with an NIH-trial examining the
effectiveness of rituximab – a chimeric monoclonal antibody against the protein CD20,
primarily expressed by B-cells – for systemic sclerosis-associated PH (NCT01086540).
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Figure 5. Participation of the immune system in pulmonary vascular remodelling.

REVIEW: PATHOBIOLOGY OF PAH

N.F. VOELKEL ET AL.

Endothelial injury
(e.g. viral infection,
toxin, antibodies,
shear stress)

Macrophage
Mast
cell

Viral infection
Connective tissue disease
Genetic defect in
immune tolerance

T-cell

1
Decreased
T-regulatory
activity

Exposed
endothelial
antigen

Two-hit diesase initiation
Pulmonary endothelial injury
+ defect in immune regulation

2

Autoreactive
B-cell
Anti-endothelial
cell antibodies
Endothelial
apoptosis

Stem Cell

Impaired injury
resolution

Precursor stem cell
in adventitial niche
Haemangloblast
HSC
Dendritic cell

Myofibroblast

Vasa vasorum

Mast cell

Megakaryocyte

FIGURE 2.

Bone
marrow

Participation of the immune system in pulmonary vascular remodelling. The initial arteriolar endothelial cell injury can be due to mechanical stress, toxins or

antibodies. The ‘‘two-hit’’ hypothesis considers that defective immune regulation, such as in HIV/AIDS and scleroderma, participates in the lumen-obliterating cell growth [1]
and in the impaired injury resolution [2]. The disease model depicted here reflects the complexity of multicellular interactions within and around the vascular wall and the
active role of the bone marrow and inflammatory and immune cells in the pathobiology of pulmonary arterial hypertension. The multi-growth factor-producing mast cell was
the first of several immune cells to be identified in the perivascular space of pulmonary arterioles in lungs from patients with severe pulmonary hypertension. It may populate
these vessels because of hyperplasia (in situ expansion of mast cell number) or after being recruited from the bone marrow. An impaired activity of regulatory T-cells may
facilitate the angio-obliteration. HSC: hematopoietic stem cell.

PAH patients, in comparison to normal subjects [88, 89].
However, increased, 18FDG uptake does not seem to correlate
with disease severity. A recent study showed no difference in
18
FDG uptake between NYHA class II and class III PAH patients,
even when there was a clear-cut difference in cardiac output [90].
Moreover, this study found no correlation between RV 18FDG
uptake and RV mechanical efficiency. It is important to remember
that 18FDG uptake studies have limitations and that the
physiological interpretation is not straightforward. Tracer uptake
can be influenced by multiple factors [91]. Moreover, 18FDG
avidity represents the total amount of 18FDG present in the tissue
at the time of image acquisition [92], which is not necessarily
equal to the total amount of 18FDG absorption by the cell. Instead,
the scan also captures the 18FDG present in the blood and
intercellular spaces. Perhaps the most prominent limitation of
18
FDG study interpretation is explained by its chemical structure.
18
FDG lacks the functional hydroxyl group that is required for the
enzyme phosphoglucose isomerase (the second enzymatic step of
glycolysis) to function properly [93]. Briefly, 18FDG cannot be
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further metabolised inside the cells. Thus, 18FDG uptake studies
are too crude to identify a ‘‘metabolic switch’’ in the failing RV.
Whereas, experimental studies have demonstrated that RVF
exhibits increased expression of glycolysis-related genes [94] and
increased enzymatic glycolysis rates [95], a complete characterisation of RV ‘‘metabolic remodelling’’ in human PAH-associated
RVF is still lacking.
Noninvasive imaging technologies, in particular echocardiography and cardiac magnetic resonance imaging (CMRI), are
now providing a more complete assessment of the structural
and functional changes of the failing and non-failing RV in the
setting of chronic PAH. Whereas changes in longitudinal
shortening (tricuspid annulus plane systolic excursion) have
been the standard measure to evaluate RV dysfunction [96],
other changes in RV morphology have been shown to correlate
with survival. For example, a large RV volume and impaired
left ventricular filling, assessed by CMRI, are strong independent predictors of mortality and treatment failure [97]. It has
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Figure 5. The initial arteriolar endothelial cell injury can be due to mechanical stress,
toxins or antibodies. The ‘‘two-hit’’ hypothesis considers that defective immune
regulation, such as in HIV/AIDS and scleroderma, participates in the lumen-obliterating
cell growth [1] and in the impaired injury resolution [2]. The disease model depicted here
reflects the complexity of multicellular interactions within and around the vascular wall
and the active role of the bone marrow and inflammatory and immune cells in the
pathobiology of pulmonary arterial hypertension. The multi-growth factor-producing
mast cell was the first of several immune cells to be identified in the perivascular space of
pulmonary arterioles in lungs from patients with severe pulmonary hypertension. It may
populate these vessels because of hyperplasia (in situ expansion of mast cell number) or
after being recruited from the bone marrow. An impaired activity of regulatory T-cells
may facilitate the angio-obliteration. HSC: hematopoietic stem cell. Copyright 2012.
Reproduced with permission of the publisher from Voelkel NF et al, et al. Pathobiology
of pulmonary arterial hypertension and right ventricular failure. Eur Respir J. 2012
Dec;40(6):1555–1565
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It is becoming apparent that circulating factors can likely amplify lung vascular injury,
attract immune cells and/or repair cells which respond to a variety of chemotactic stimuli,
suggesting perhaps, a systemic disease component contributing to the development or
progression of PAH. In the “modern era” of PAH treatments, where standard vasodilation
therapies have failed to reverse or stop the progression of PAH, novel targets such as
discrete immune pathways hold promise. However, new drugs and clinical trials will
require to assess which patients may respond to anti-inflammatory treatment strategies.
2.5 Summary and Conclusions
PAH is increasingly recognized not as one disease but as a group of diseases where
genetic susceptibility renders patients vulnerable to a chronic pulmonary
microangiopathy. Further explorations of the molecular mechanisms of cell
reprogramming in PAH, in both the lung vessels and the heart, should lead to a better
understanding of this group of diseases. The classical pathophysiology of PAH which
operates with the mechanical concepts of pressure, flow, shear stress, RV wall stress and
impedance, should be complemented with the new pathobiological concepts of cell injury
and repair and interactions of complex multicellular systems (Figure 6). Precursor-and
stem cells derived from the bone marrow and resident lung vascular stem cells should
also be considered as active players in the process of pulmonary vascular wound healing
“gone awry”. Integrating the new pathobiological concepts will become critical as we
design new medical therapies in order to change the prognosis of the patients with this
fatal group of diseases.
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Figure 6. Integration of haemodynamic and cellular events that characterise the
cardiopulmonary disease of severe pulmonary arterial hypertension (PAH).
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Integration of haemodynamic and cellular events that characterise the cardiopulmonary disease of severe pulmonary arterial hypertension (PAH). The

pathophysiology of PAH, which operates via mechanical concepts, is complemented with concepts of cell injury and repair and interactions of complex multicellular systems.
The model is built on the principle of abnormal pulmonary blood flow. Regional blood flow abnormalities underlie the pulmonary vascular remodelling, which in turn causes
further alterations of the regional blood flow, perpetuating a cycle of cell death and cell proliferation. Vascular rarefaction occurs in the form of pruning of the small lung
vessels, and in the right ventricle in the form of myocardial capillary rarefaction.
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Figure 6. The pathophysiology of PAH, which operates via mechanical concepts, is
complemented with concepts of cell injury and repair and interactions of complex
multicellular systems. The model is built on the principle of abnormal pulmonary blood
flow. Regional blood flow abnormalities underlie the pulmonary vascular remodelling,
which in turn causes further alterations of the regional blood flow, perpetuating a cycle of
cell death and cell proliferation. Vascular rarefaction occurs in the form of pruning of the
small lung vessels, and in the right ventricle in the form of myocardial capillary
rarefaction. Copyright 2012. Reproduced with permission of the publisher from Voelkel
NF et al, et al. Pathobiology of pulmonary arterial hypertension and right ventricular
failure. Eur Respir J. 2012 Dec;40(6):1555–156
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Chapter 3: Function and Dysfunction of The Right Ventricle

Segments of this chapter have been previously published in:
Gomez-Arroyo J et al. Differences in Right Ventricular Remodeling Secondary to
Pressure-Overload in Patients with Pulmonary Hypertension. Am J Respir Crit Care Med.
2013. In Press.
Voelkel NF, Gomez-Arroyo J, et al. Mechanisms of right heart failure-A work in
progress and a plea for failure prevention. Pulm Circ. 2013 Jan;3(1):137–143.
.
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CHAPTER 3

"Severe damage of right ventricle free wall (of the dog) had no apparent effect on
hemodynamics.”
Starr I., et al.
American Heart Journal, 1943

3. 1 Introduction
The right ventricle (RV) of the heart, which pumps blood through a low pressure, low
resistance “lesser” circulation, is now receiving more attention by researchers and
clinicians, after many years of benign neglect(23, 30, 85, 246). Some of the many
reasons for neglecting the RV assumed that 1) In the context of global cardiac
performance the RV was not very important (246) and 2) That the cellular and molecular
mechanisms of RV failure (RVF) were not different from those responsible for LV
failure. Perhaps the biggest knowledge gap originated from the lack of experimental
studies modeling the development of RVF, and from attempts to extrapolate mechanisms
of chronic RVF from studies originally designed to study acute RVF. These likely
explain why “pressure overload” is the most frequent – and sometimes exclusively –
quoted mechanism of RVF. Indeed, patients with chronic, progressive pulmonary
vascular disease, most frequently die of RV failure(249). However, as we increment our
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knowledge in the pathobiology of RVF, we should also begin to consider RVF as a
“progressive,” but not necessarily “chronic” phenomenon.
3.2 The case for investigating the Right Ventricle
We propose that the outcome of the patient with pulmonary arterial hypertension (PAH)
is not only determined by pathophysiological characteristics germane to the lung disease
– vasoconstriction and pulmonary vascular remodeling – but rather by the response of the
RV to increased afterload and to additional mechanistically important factors imposed on
the RV such as neuroendocrine system activation (23, 26) and perhaps, factors released
from a “sick-lung circulation” (243)(Figure 7). In the management of patients with
severe PAH we still face (as a barrier) the fact that prevention of RV failure is not a
realized treatment goal. For the past 15 years, clinical studies have utilized vasodilator
drugs expecting to significantly reduce pulmonary arterial pressure, halt or delay the
progression of the lung vascular disease, reduce RV afterload and prevent the
development of RVF. However, this goal is not often accomplished in the clinical setting,
as a recent meta-analysis of PAH clinical trials reported a weighted mean reduction in
mean pulmonary arterial pressure of 3 mmHg after treatment(72). Moreover, it has been
demonstrated that even after many years of vasodilator therapy (at least with
epoprostenol treatment), pathological lung vascular remodeling does not stop(213).
Lastly, a recent cardiac MRI study from the Netherlands’ pulmonary hypertension center
reported that the survival of medically treated patients with PAH was not determined by a
vasodilator-induced decrease of the pulmonary vascular resistance, but rather by an
improved RV ejection fraction (RVEF) (237).
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Figure 7: The sick lung circulation–right heart failure axis.
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right ventricular hypertrophy. The structural and functional changes during the development of right ventricular failure can be characterised clinically [2]. Right ventricular
dysfunction is probably associated with multiple cellular changes [3], such as oxidative stress, apoptosis, inflammation, fibrosis and metabolic remodelling. These factors
also contribute to right ventricle (RV) dysfunction and failure. The cellular changes are either the result of chronic RV pressure overload or the effect of circulating factors
released from the sick lung circulation. RVF: right ventricle failure; LV: left ventricle.

also been reported that decreased RV longitudinal shortening
and free-wall motion at the time of diagnosis do not
significantly change over time, whereas RV transverse shortening continues to decline over time in non-survivor PAH
patients [98]. RV transverse shortening could be particularly
valuable for the monitoring of treatment success or failure, as
we move forward with clinical trials for RV-targeted therapies.
Measurement of RV free wall longitudinal deformation (strain)
and the rate of deformation by speckle-tracking strain echocardiography have been shown to identify patients with greater
severity of RV dysfunction [99]. Most importantly, changes in
RV strain correlate significantly with functional class and can
predict mortality. Finally, the prognostic importance of RVF in
patients with PAH has recently been revisited. VAN DE
VEERDONK et al. [100] reported that although elevated PVR (in
treated PAH patients) is associated with higher mortality, the
RV ejection fraction (measured by CMRI) is the strongest
predictor of survival, even after a response to vasodilator
therapy has been established. Other noninvasive imaging tools
to evaluate RV dysfunction in PAH patients have been
described previously [101–104].
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CHALLENGES OF PAH TREATMENT
The future of the medical management of PAH faces multiple
obstacles. 1) In spite of improved screening tools, PAH is not
discovered during its early stage and treatment is often
delayed. Data from the REVEAL registry indicate that the
lag-time from the onset of symptoms to right heart catheterisation has not changed compared with the data published
based on the first National Institute of Health registry [105]. 2)
Although improvements in survival have been demonstrated
in clinical trials, the overall patient survival in the ‘‘modern
era’’ remains low and the survival of ‘‘incident’’ PAH patients
appears to be similar to that of the idiopathic PH patients
enrolled in the first National Institute of Health registry [8].
Indeed, the concept of vasodilator drug treatment for PAH has
become controversial in the last decade (for reasons discussed
previously). In one meta-analysis, MACCHIA and co-workers
[106, 107] called PAH ‘‘a clinical condition looking for new
drugs and research methodology’’ and stated ‘‘whether current
therapies of PAH improve long-term survival has never been
demonstrated in a randomised clinical trial’’. However, the
meta-analysis of MACCHIA and co-workers [106, 107] was
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Figure 7: Increased pulmonary vascular resistance generates a significant afterload for
the right ventricle resulting in right ventricular hypertrophy. The structural and functional
changes during the development of right ventricular failure can be characterized
clinically(249). Right ventricular dysfunction is probably associated with multiple
cellular changes(23), such as oxidative stress, apoptosis, inflammation, fibrosis and
metabolic remodelling. These factors also contribute to right ventricle (RV) dysfunction
and failure. The cellular changes are either the result of chronic RV pressure overload or
the effect of circulating factors released from the sick lung circulation. RVF: right
ventricle failure; LV: left ventricle. Copyright 2012. Reproduced with permission of the
publisher from Voelkel NF et al, et al. Pathobiology of pulmonary arterial hypertension
and right ventricular failure. Eur Respir J. 2012 Dec;40(6):1555–1565.
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Thus, if current vasodilator drugs have failed to reverse the vascular disease, should we
not start thinking about RV-targeted therapies while we wait for new PAH lung-specific
therapies to get in the pipeline?

The prevailing paradigm holds that increased RV afterload is sufficient as an explanation
of RV failure, but there are several conflicts with this view:

•

Under most circumstances the RV adequately adapts to chronic pressure overload
(in contrast to acute pressure overload). In average, at least 55% of incident
patients with PAH live (with chronic progressive pressure overload) for 3
years(22).

•

Even in the pre-pulmonary hypertension “drug era” (prior to 1991) there were
long-term PAH patient survivors(241), most prominently patients diagnosed with
aminorex- (appetite suppressant) induced PAH(127).

•

There are patients with severe PAH that remain highly functional (NYHA
functional class I) for many years without developing RV failure(22).

•

Experimental studies show that after pulmonary artery banding (PAB), the RV
develops adaptive hypertrophy which is more resistant to pressure overload and
does not necessarily develop failure(25).

Perhaps, the best example to argue against pressure-overload as the unique insult
responsible for the development of RVF are the patients with Einsemenger Syndrome.
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3.3 Differences in Right Ventricular Remodeling Secondary to Pressure-Overload in
Patients with Pulmonary Hypertension: The ‘Unique’ Right Ventricle of Patients
with Eisenmenger Syndrome

Patients with Eisenmenger Syndrome (EMS), develop PAH secondary to a systemic-topulmonary shunt. In other words, a congenital heart defect (mainly nonrestrictive posttricuspid defects) initially allows blood to shunt the left side compartment to shunt
towards the right ventricle or pulmonary artery, either by means of a ventriculoseptal
defect or a patent ductus arteriosus. If not corrected a certain age, the shunt allows large
amounts of blood to be pumped into the lung circulation (volume-overload) and this
overload eventually leads vascular remodeling and pulmonary hypertension(97). Once
PH has developed, the pressure in the right ventricle will eventually be high enough to
reverse the shunt and pump venous (deoxygenated) blood into the left (systemic)
circulatory compartment, explaining the remaining features of the Eisenmenger
syndrome: Cyanosis, chronic hypoxemia, polycythemia and finger clubbing(97)..
Most importantly, the ‘resilient’ RV of EMS patients appears to be better adapted to
increased pressure-overload compared to the RV of patients with idiopathic PAH (IPAH)
or other forms of PAH(98). Indeed, whereas most patients with IPAH frequently present
with decreased cardiac output at the time of diagnosis(22), patients with EMS maintain a
normal cardiac output and right atrial pressure in spite of a similar degree of pressure
overload(96), at least until later stages of the disease(96). Interestingly, whereas the
hemodynamic differences between IPAH and EMS patients have long been
recognized(96), and some structural differences of the RV have been described by
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cardiac tomography(98), an anatomo-pathological comparison between the hearts of
patients with EMS and IPAH has so far not been reported.
As a preliminary project, we performed a post-mortem morphometric analysis of the left
and right ventricles of patients with IPAH (n=6) or EMS (n=6) who died from RV
failure, and sought to characterize the differences in RV hypertrophy.
3.3.1 Patient’s characteristics and methods

All patients with EMS included in this study had a patent ductus arteriosus as the
systemic-to-pulmonary shunt. Age-matched patients who died from non-cardiac, nonpulmonary disease where used a controls (n=6). The majority of patients died before any
PAH-specific therapies were available. However, we excluded any patient that had been
treated with PAH-specific drug later in time. Informed consent was obtained from the
family of each patient. The study protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki and was approved by the Instituto Nacional de Cardiología
"Ignacio Chávez” Institutional Review Board.
We measured the anterior-to-posterior and septum-to-free-wall diameters, as well as RV
and LV wall thickness at the base, middle and apex levels (Figure 8A-B). Annular
dimensions of tricuspid and mitral valves were also measured. Utilizing the RV diameters
we estimated the RV-chamber area using the formula A= (π * dAP * dSW)/4, were A
represents the RV-chamber area, ChamberArea =

!*!"#*!%&
!

dAP represents the anterior-

to-posterior diameter and dSW represents the septum-to-free wall diameter. This formula
was derived from the formula to calculate the area of a circle. All results are reported as
mean ± standard deviation. Differences between groups were assessed by one-way or
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two-way ANOVA and a Bonferroni’s post-hoc test was used to assess significant
differences between groups. A p-value< 0.05 was accepted as significant. Correlation
analysis was done using a Spearman’s test.
The mean age for all groups was 28 ± 10 years. Both EMS and IPAH patients had severe
pulmonary hypertension (56 ± 14 mmHg in IPAH versus 78 ± 14 mmHg in EMS,
p=0.023). Figure 8C-E illustrates that the RV in both groups of patients responded to
pressure-overload with significant hypertrophy as evidenced by increased RV wall
thickness. Interestingly, EMS patients also exhibited increased left ventricular (LV) wall
thickness at the base and middle levels but not at the apex level (Figure 8F-H). In
contrast to what has been reported by cardiac magnetic resonance in patients with
increased RV afterload secondary to chronic thromboembolic pulmonary
hypertension(89), we did not find a reduction in LV wall thickness in the group of
patients with IPAH. Figure 9A-C illustrates the correlation between the wall thickness at
the base, middle and apex levels with their respective RV-chamber area. Patients with
IPAH developed significant RV hypertrophy compared to control right ventricles but
significantly less hypertrophy compared to EMS patients. Most importantly, compared to
EMS group, the RV of IPAH patients had significantly less hypertrophy (RV thickness)
in relationship to the RV-chamber area (Figure 9A-C) and this relationship between area
and wall thickness seemed to be more disproportionate at the apex level.
It should be noted, however, that EMS patients had significantly a higher mean
pulmonary arterial pressure and this finding could in fact explain the differences in RV
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Figure 8. Right and Left Ventricles Wall Thickness in Patients with Pulmonary Arterial
Hypertension
Figure 1
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Figure 8. A-B) Schematic representation and gross anatomy of the RV illustrating the
location where each measurement level was taken. C-E) Right ventricular posterior wall,
anterior wall and free wall thickness at base, middle or apex segment levels. F-H) Left
ventricular posterior wall, anterior wall and free wall thickness at base, middle or apex
segment levels. Figure was reprinted with permission of the American Thoracic Society.
Copyright © 2013 American Thoracic Society Gomez-Arroyo J et al. Differences in
Right Ventricular Remodeling Secondary to Pressure-Overload in Patients with
Pulmonary Hypertension. Am J Respir Crit Care Med. 2013. In Press.
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hypertrophy. However, as it can be appreciated in Figure 9F-H, the LV of these patients
is also larger and thicker, which could suggest the presence of a stimuli, not directly
associated with increased RV pressure-overload, that lead to generalized growth of the
heart. However, to what extent the remodeling of the RV in EMS patients is independent
of pressure-overload will remain to be investigated. Interestingly, despite the fact that the
RV of EMS patients was exposed initially to volume and later by pressure-overload, the
RV underwent concentric (Figure 9M) rather than eccentric hypertrophy. This is a
particularly interesting finding given the fact that volume-overload of the left ventricle
frequently leads to dilated cardiomyopathy. It is also important to underline that all
patients in the EMS group had a post-tricuspid defect (patent ductus arteriosus) and our
findings may not be true for all congenital heart defects leading to Einsenmenger
physiology. For instance, it has been shown that pre-tricuspid defects (such as atrial
septal defects) exhibit different cardiac remodeling compared to post-tricuspid defects
(98). To further investigate cardiac remodeling in the two groups of patients, we analyzed
collagen deposition by Masson Trichrome staining. We demonstrated that both
conditions were associated with significant perivascular and interstitial RV fibrosis
(Figure 9 K-L). However, EMS patients appear to exhibit less RV fibrosis, which could
contribute to better diastolic function. The mechanisms underlying the difference in the
amount of cardiac fibrosis will remain to be investigated.
In the aggregate, based on the data derived from our study of patients with ESM
and from the current literature, one could suggest that chronic, progressive
pressure overload might be the initial component responsible for triggering
maladaptive changes in the RV, however, not necessarily the only one. Other factors
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such as ischemia, inflammation, oxidative damage, epigenetics and abnormal cardiac
energetics could equally contribute to the development of RVF (Figure 7).

Figure 9. Correlation Between Wall Thickness and Chamber Area in Patients with
Pulmonary Arterial Hypertension
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EMS"

Figure 9. A-C) Correlation between free wall thickness and RV chamber area.
Horizontal and vertical whiskers represent the standard error bars for both variables. J)
Autopsy material shows the thin RV-free wall (asterisk) of a patient with idiopathic
pulmonary hypertension (IPAH), compared to the RV of an Eisenmenger’s Syndrome
patient (M). K-L) Micrographs of Masson Trichromatic-Stained slides illustrate
significant collagen deposition (blue) in the RV of the IPAH patient compared to the
EMS patient (O-P). Figure was reprinted with permission of the American Thoracic
Society. Copyright © 2013 American Thoracic Society Gomez-Arroyo J et al.
Differences in Right Ventricular Remodeling Secondary to Pressure-Overload in Patients
with Pulmonary Hypertension. Am J Respir Crit Care Med. 2013. In Press.
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3.4 Mechanisms of Right Ventricular Failure

3.4.1 Right ventricular ischemia
Patients with severe PAH can develop chest pain which may be due to RV
ischemia(241). Wolferen et al (239) have shown changes in the right coronary artery
blood flow pattern in patients with PAH, while Gómez, Sandoval and collaborators
employed stress myocardial scintigraphy using technetium sestamibi to demonstrate RV
ischemia associated with a RV end-diastolic pressure elevation(83). Unfortunately human
histological studies of the RV from patients with chronic severe PAH are unavailable,
and it has never been demonstrated whether the ratio of RV muscle-to-capillary density,
in patients with severe PAH, is altered as it has been reported in LV failure or in
experimental RVF(25). Hein et al studied LV tissue biopsies obtained at the time of heart
surgery for aortic stenosis valve replacement, and described capillary rarefaction and
discuss their finding of autophagy. In order to explain RV ischemia in the setting of PAH,
investigators have pointed towards increased RV-wall stress (92) and myocardial fibrosis,
but it is presently unclear whether RV-wall microcirculation impairment, RV wall stress,
RV fibrosis – or all these factors in combination – conversely contribute to RV
myocardial ischemia. In the SU5416/ chronic hypoxia (Su/Hx) model of severe PAH and
RV failure (to be discussed in Chapter 4) (25), Bogaard et al. have demonstrated a
dramatic reduction in the number of perfused myocardial capillaries using in vivo tomatolectin endothelial cell (EC) labeling. Histologically we have also showed diffuse
myocardial fibrosis(25). Capillary rarefaction has also been reported in the monocrotaline
(MCT) model of PAH(86). Surprisingly, the capillary density in the RV from rats with
pulmonary artery banding (mechanically induced RV hypertrophy) is only mildly
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decreased [17]. We asked whether the Su/Hx model of PAH presents with additional
functional alterations of the remaining RV capillaries. Thus, we used electron microscopy
to show damaged EC in cardiac capillaries (Figure 10).
Based on our results, we propose three mechanisms that could account for the capillary
rarefaction observed in experimental RVF: 1) EC apoptosis and/or 2) Endothelial cell
mesenchymal transformation, as proposed by Zeissberg et al(268). 3) Insufficient
angiogenesis in a context of rapid myocardial hypertrophy. EC death could be partially
explained by a decreased expression of the angiogenic protein vascular endothelial
growth factor (VEGF), as it has been observed in the failing RV from Su/Hx animals(25).
This hypothesis is largely based on the data generated by Eli Keshet’s group, which has
shown that genetically engineered, reversible reduction of VEGF expression in the mouse
myocardium results in capillary rarefaction, suggesting that VEGF signaling is necessary
for the maintenance of myocardial capillaries(140). Handoko et al and others have also
reported decreased VEGF and RV-capillary rarefaction in rats treated with MCT(86,
168). Taken together, the work from several laboratories supports the notion that there
are microcirculatory problems in the failing RV. However, whether impaired
microcirculation function is sufficient to explain the rest of maladaptive changes
observed in the failing RV remains to be investigated.
3.4.2 Inflammation
As mentioned in Chapter 2, the role of a dysregulated immune system in the
pathobiology of human PAH has become more apparent in recent years (90, 158, 251).
Interestingly, only one single study has reported leukocyte infiltration in the right
ventricles obtained from patients with idiopathic PAH (IPAH) and PAH associated with
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systemic sclerosis (SScPAH) (165). The authors reported a higher number of CD45+ and
CD68+ cells in SScPAH when compared with RV samples from IPAH patients.
Although inflammatory cells have been localized in the RV from rats with
monocrotaline-induced PAH(81, 86), no systematic study has been undertaken to
examine the role of inflammatory cells or inflammatory mediators in RV failure. A recent
experimental study of LV failure in mice generated a novel concept of a toll-like receptor
9 (TLR-9) – dependent failure component. In this model of chronic severe LV pressure
overload mitochondrial DNA from damaged heart cells generated a cardiac inflammatory
response via TLR 9(163).
3.4.3 Oxidative Stress
Oxidative cell damage and oxidant-dependent transcriptional control occur and
participate in inflammatory organ and tissue responses. Little is known about the role of
oxidant stress in RV failure with the exception of the important study of Yet et al(264).
These authors exposed hemeoxygenase-1 KO mice to 5 weeks of chronic hypoxia and
found that the RV, but not the LV was damaged and dilated. Thus, it appears that the
HO-1 function is required for a successful adaptation of the RV to pressure overload.
The expression of HO-1 in the RV tissue from the Su/Hx pulmonary hypertensive rats is
reduced, perhaps reflecting an impaired response to oxidant stress(25).
3.4.4 MicroRNA
Several recent publications have demonstrated microRNA dependent regulation of gene
expression in association with pulmonary artery cell growth (44, 57, 180) and plasma
microRNA expression patterns after acute myocardial infarcts or in patients with right
heart failure (185). In mouse models, miRNAs play a role in the development of heart
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Figure 10. Electron Microscopy Demonstrating Damaged Capillaries in Right
Ventricular Failure Tissue
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Figure 10. Micrographs obtained by electron microscopy demonstrate the presence of
“blebbing” (A, arrow) and holes (B, arrow) which are a representation of endothelial cell
damage of the microvessels of RV tissue obtained from rats with severe pulmonary
hypertension and right ventricular failure. Figure C is a microphotograph of RV tissue
obtained from a rat with RV failiure, stained with a Masson-Trichromatic staining which
marks collagen in blue.
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failure and the literature on cardiac microRNAs is still expanding(238). The transition of
the RV from hypertrophy to failure has been investigated in the rat Su/Hx model and we
reported a decrease in miR 21,34c, 133a and 139-3p in Su/Hx-induced RV failure when
compared to PAB-induced RV hypertrophy(55). More recently Reddy et al reported RVspecific microRNA expression changes in a murine model(185). Unfortunately, the
mechanisms by which miRNAs could affect gene and protein expression during RVF, are
incompletely understood.
3.4.5 Other mechanisms: Apoptosis, fibrosis and mitochondrial dysfunction
Indeed, other mechanisms could contribute to the development of RV failure, by directly
affecting the contractile machinery. For instance, Bogaard et al. in our group has
demonstrated that RV tissue obtained from animals with severe RVF exhibit positive
Terminal deoxynucleotidyl transferase dUTP nick end (TUNEL) staining which is
utilized to label cells with severe DNA damage and serves as a surrogate marker for
cellular apoptosis(26). Cell death could potentially contribute to the formation of
replacement fibrosis which has been demonstrated in human and experimental RV failure
(Figure 9 and 10). Abnormal cardiac metabolism has long been recognized as a problem
in chronic left heart failure(156, 220). Similarly, data derived from experimental models
of PH suggest that the failing RV is also characterized by a certain degree of “metabolic
remodeling”. In the SU/Hx rat model, the RV exhibits increased expression of glycolysisrelated genes(55), whereas dysfunctional RV hypertrophy in the monocrotaline rat model
of PH is associated with increased glycolysis enzymatic rates(176). Unfortunately, a
complete characterization of RV “metabolic remodeling” in human PAH is still lacking.
Positron emission tomography studies have shown increased accumulation of the glucose
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analog 18F-2-Deoxy-2-Fluoro-D-Glucose (18-FDG) in the RV of PAH patients(35, 161).
However, 18-FDG uptake studies have multiple limitations and the physiological
interpretation is not straightforward (i.e 18-FDG uptake studies do not directly measure
glycolysis). RV oxygen consumption can also be measured by [11C]-acetate PET
scanning(259). However, such studies are limited to a few specialized centers and are
difficult to perform(249). Based on these studies, we sought to characterize the metabolic
transcriptional profile and mitochondrial function of RV tissue in normal, adaptive and
maladaptive RV hypertrophy. The results are presented and discussed in Chapter 5.
3.5 Summary and Conclusion
Right heart failure is characterized by morphological and functional changes. We wish to
advance the concept that the RV afterload by itself is insufficient as an explanation of the
mechanism of RV failure. Other factors should be taken into account when studying and
treating RVF, as they pose a critical paradox: While the remodelled lung circulation in
PAH is characterized by angiogenesis, apoptosis-resistance and cell proliferation
(Chapter 2), the failing RV suffers from ischemia(83), capillary rarefaction and
cardiomyocyte apoptosis(25), conditions that could be worsened by pharmacotherapy
targeting pulmonary vascular remodelling.
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Chapter 4: Animal Models of Pulmonary Arterial Hypertension and Right
Ventricular Chronic Pressure-Overload

Segments of this chapter have been previously published in:

Gomez-Arroyo JG, et al The monocrotaline model of pulmonary hypertension in
perspective. Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15;302(4):L363–9.

Gomez-Arroyo JG, et al A Brief Overview of Mouse Models of Pulmonary Arterial
Hypertension: Problems and Prospects. Am J Physiol Lung Cell Mol Physiol. 2012 May
15;302(10):L977-91
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CHAPTER 4

4.1 Introduction
Animal models of disease are of pivotal importance for the investigation of normal organ
function, the pathobiology of frequent and rare disorders as well as for preclinical proof
of principle treatment studies. As mentioned in the previous Chapters, it has been
increasingly noticed that there is a substantial gap between our knowledge of left
ventricular and right ventricular failure (RVF) mechanisms and that the concepts of RVF
mechanisms have been mainly adapted from models of left ventricle failure or
extrapolated from models of acute RVF(246).
Different animal models of pulmonary hypertension have been described many
investigators and therefore, the aim of this Chapter is to briefly describe the current
models of adaptive and maladaptive RV hypertrophy with or without lung vascular
remodeling. This Chapter also provides the rationale for using the SU5416/hypoxia
model for the experiments conducted for this dissertation and discusses the pros and cons
of the other models such as the Monocrotaline-injury rat model. Lastly, we discuss the
limitations of genetically engineered mice for the study of PH and RV failure.
4.2 The Monocrotaline-injury Model of Pulmonary Hypertension in Perspective
For the past three decades, two rat models have been central to the investigation of
pulmonary hypertension (PH): The chronic hypoxia exposure model and the
monocrotaline (MCT) lung injury model (215). Although the mechanisms of hypoxiainduced vascular remodeling are understood to some degree, the complex obliterative
lesions found in human patients with severe PAH do not develop in this rodent model
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(248). The monocrotaline rat model continues to be a frequently investigated model of
PAH as it offers technical simplicity, reproducibility and low cost compared to other
models of PAH. While the MCT rat model has contributed to a better understanding of
vascular remodeling in pulmonary hypertension. However, multiple features of the
“monocrotaline syndrome” do not resemble human PAH: liver failure, lung injury and
myocarditis. Therefore, based on a literature review and our current data we questioned
whether this model remained productive as a preclinically relevant model of severe
plexogenic PAH.
4.2.1 Monocrotaline pyrrole toxicity and the “monocrotaline syndrome”
Monocrotaline (MCT) is an 11-membered macrocyclic pyrrolizidine alkaloid derived
from the seeds of the Crotalaria spectabilis plant (Figure 11A and B). The MCT
alkaloid is activated to the reactive pyrrole metabolite dehydromonocrotaline (MCTP) in
the liver, a reaction that is highly dependent on CYP3A4 (cytochrome p450) (187, 257).
Specific metabolic inducers of this cytochrome increase the MCTP production by the rat
liver, whereas specific anti-CYP3A4 antibodies inhibit it (114, 187). When ingested,
MCT induces a syndrome (Table 2) characterized – among other manifestations – by
pulmonary hypertension, pulmonary mononuclear vasculitis (acute necrotizing
pulmonary arteritis in about one-third of the animals) and right ventricular hypertrophy
(117, 125).
Although it has been reported that MCT injures pulmonary endothelial cells (190) (117),
the exact toxicological mechanisms by which MCT initiates lung toxicity remain unclear.
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Table 2.

Characteristic

Dose

Reference

range
(mg/kg)
Acute lung injury

60 -100

(58, 122, 188, 200, 216)

Interstitial pulmonary fibrosis

2.4 - 100

(91, 145, 146)

Necrotizing pulmonary

Not

(117, 125, 257)

arteritis

quantified

Pulmonary hypertension

45 - 60

(27, 117, 159, 176, 198, 200, 266, 267)

RV hypertrophy

45 - 60

(27, 34, 86, 117, 159, 176, 198, 200, 266,
267)

Myocarditis

50 - 60

(4, 34, 86)

Hepatic venooclusive disease

60 - 300

(41-43, 47, 48, 51, 60, 138, 142, 170, 256,
257)
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Lee and Sehgal, have shown that pulmonary arterial endothelial cells (PAEC) exposed to
MCT develop megalocytosis characterized by an enlarged Golgi apparatus, displacement
of endothelial nitric oxide synthase and decreased cell-surface/caveolar nitric oxide
(128). MCT-treated endothelial cells demonstrate marked disruptions of intracellular
membrane trafficking that affect several cell membrane proteins (204). Huang and
Mathew have reported that MCT-induced loss of membrane proteins, results in the
activation of proliferative and antiapoptotic factors, and deregulation of nitric oxide
signaling, leading to lung vascular changes (100). The initial MCT-induced endothelial
cell damage has also been linked to BMPRII (Bone Morphogenetic Protein Receptor II)
dysfunction and BMP signaling disruption, as well as increased expression of
intracellular elements involved in the sequestration and inhibition of the BMPR II activity
(184). Nakayama and Wilson demonstrated that in human PAEC, the monocrotaline
pyrrole significantly induced the Nrf2-mediated stress response pathway and increased
caspase-3 activation (154).
Paradoxically, although there is vast evidence to suggest that MCT elicits PAEC
dysfunction in multiple levels, the MCT PAH model is characterized predominantly by
pulmonary arterial medial hypertrophy (Figure 11D) but not by endothelial cell-mediated
angioobliteration, as it is present in the human disease or in the SU5416/hypoxia model
of severe PAH (Figure 11E). It remains unclear whether an initial MCT-induced damage
of pulmonary endothelial cells stimulates smooth muscle cell proliferation and/or
endothelial cell mesenchymal transition; it is also elusive whether endothelial cell
dysfunction is a consequence of non-PAEC damage or systemic inflammation triggered
by MCT exposure. A detailed mechanistic explanation connecting the initial endothelial
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cell injury and subsequent medial hypertrophy is still missing. Another major concern is
the relation between the kinetics of MCT and development of pulmonary hypertension.
MCT causes a short intense insult with a rapid loss of the starting compound because
MCTP is rapidly degraded in aqueous solutions such as plasma (32, 63, 257). Of interest,
significant changes in pulmonary artery pressures, medial thickness of small pulmonary
arteries and RV hypertrophy do not occur until the third or fourth week after MCT
exposure (124, 235). This issue has been partially explained by the accumulation of
MCTP in erythrocytes, where it conserves its capability to interact with lung tissue (63,
166, 257). Furthermore, although a time-dependent effect of MCT has been described
(88, 235), an adequate dose-response study has not yet been reported.
Many publications have demonstrated pulmonary vessel remodeling in MCT-treated rats
and dogs, leading to pulmonary hypertension (84, 215, 257). Mitchel Botney (164)
originally described that when used in combination with pneumonectomy (a “second
hit”), MCT-treated rats developed angioobliterative changes in the pulmonary vasculature
resembling those of human disease or the SU5416/hypoxia rat model (255). However,
plexiform-like vascular lesions have not been described after a “single hit” of
monocrotaline alone, while other pathological changes have been reported as a
consequence of MCT exposure. MCT not only injures the pulmonary arteries, but also
induces alveolar edema, alveolar septal cell hyperplasia and occlusion of pulmonary
veins (58, 126). MCT-induced interstitial pulmonary fibrosis has also been described in
mice (with variable doses and timepoints) (58, 91). Electron micrographs of MCT-treated
animals, revealed degeneration of both lung endothelial and type I epithelial cells, as well
as marked interstitial hypercellularity and fibrosis (145, 146). Hayashi and Hayashi
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reported that a single dose of 100 mg/kg, is sufficient to induce severe pulmonary fibrosis
and/or interstitial pneumonia in mice (91), whereas other investigators have reported that
pulmonary fibrosis seems to be only a late manifestation of monocrotaline exposure (58).
The MCT pyrrole has also been described as an anti-mitotic agent (47, 174). In
astrocytes, the MCT pyrrole can induce DNA damage by generating DHP-derived DNA
adducts, which induce DNA-crosslinks, DNA-celullar protein conjugates and apoptosis
(154, 208, 253). MCT-induced DNA damage is reflected in persistent cell cycle arrest
and is responsible for the cyto- and karyomegaly (megalocytosis) described in
pneumocytes, human pulmonary endothelial cells, glial cells and hepatocytes of MCTtreated animals (128, 208, 256, 257). Particularly, type II pneumocytes seem to be highly
affected by MCT-induced mitotic inhibition (260), which is partially mediated by altered
polyamine metabolism (20). Confirming these previously reported data, when compared
to the SU5416/hypoxia model of angioobliterative pulmonary hypertension, the MCTtreated animals demonstrate marked perivascular edema (Figure 11F), significant
alveolar septal thickening (Figure 11G), and type I pneumocyte megakariocytosis
(Figure 11H).
4.2.2 Monocrotaline-induced myocarditis
MCT treated rats develop significant pulmonary hypertension and marked right
ventricular (RV) hypertrophy (Figure 12 A, also see references (27, 117, 176, 198, 225).
Traditional concepts suggest that the RV dysfunction of MTC-treated rats is a direct
consequence of pressure overload. Interestingly, despite having lower pulmonary artery
pressure and a similar degree of RV dysfunction compared to the SU5416/hypoxia model
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of pulmonary hypertension (Figure 12 B-C), MCT treated rats exhibit a significantly
higher mortality (Figure 12 D). Several investigators have utilized MCT to induce
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Figure 11. The monocrotaline pyrrole and the lung changes characteristic of the
monocrotaline syndrome
MONOCROTALINE MODEL IN PERSPECTIVE
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Figure 11. A: Crotalaria spectabilis, image re- produced with permission of Wendy VanDyk Evans, Bugwood.org. B: monocrotaline pyrrole chemical structure, reproduced with
permission of chembase.com-chemical com- pounds database. Monocrotaline-treated rats
(D) exhibit pulmonary vascular media hyper- trophy and mononuclear cell infiltration
compared with control rats (C). In contrast to monocrotaline-treated rats, the model of
SU5416/hypoxia (E), characterized by ab- normal endothelial cell proliferation, shows
complete vascular obliteration. In addition to the vascular changes, monocrotaline-treated
rats exhibit marked perivascular edema (F, blue line), alveolar septal thickening (G, long
arrow; arrowhead marks a normal septa), and megalocytosis of type I pneumocytes (H,
long arrows; arrowhead marks a normal type I pneumocyte nucleus).
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pulmonary hypertension, assuming that MCT has no direct cardiac effect; however,
others have investigated the potential role of load-independent maladaptive mechanisms
that could contribute to RV failure in MCT-treated rats. For instance, in addition to RV
hypertrophy, MCT treatment has been associated with increased 67Galium uptake by
scintigraphy (34) and marked neutrophil migration into the RV myocardium, even during
early stages of the monocrotaline syndrome (34). Whether this neutrophil infiltration was
a consequence of RV pressure overload or consequence of a direct cardiac effect (perhaps
microvascular endothelial cell damage) of monocrotaline remains undetermined.
Handoko et al have also demonstrated a widespread leukocyte infiltration of the right
ventricle in MCT-treated rats (86). Our own data confirm the presence of multiple
inflammatory cell foci throughout the RV (Figure 12 F-G). When characterized by
immunohistochemistry, the majority of the leukocyte infiltrates were positive for CD20, a
marker for B-lymphocytes (Figure 12 K), while CD68 (a macrophage marker) was
negative. CD8 (a cytotoxic T-cell marker) was positive as well, but to a lesser extent.
These results suggest perhaps that monocrotaline induces a lymphocytic myocarditis. We
also observed, marked infiltration of inflammatory cells within the left ventricle,
associated with coronary arteriolar wall thickening (Figure 12 H) and marked
perivascular fibrosis (Figure 12 I). The MCT-induced myocarditis may be responsible
for significant left ventricular systolic dysfunction and impaired diastolic relaxation, also
described by Akhavein and Rohlicek (4). Benoist and collaborators have described a proarrhytmogenic substrate in the hearts of MCT-treated animals (21). Whether MCTinduced myocarditis or arrhythmias (21, 144) are the cause of death in rats – which can
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Figure 12. Changes in the Right Ventricle Associated with Monocrotaline Exposure
Perspectives
L366
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Fig. 2. Both monocrotaline (MCT) and SU5416/hypoxia animals develop pulmonary hypertension, however, MCT-treated rats present with a lower degree of
pulmonary hypertension compared with the SU5416/hypoxia model (A). Both models develop a similar degree of right ventricular (RV) dysfunction assessed
by increased RV internal diameter (B) and decreased tricuspid annular planar systolic excursion (TAPSE, C), two heart rate-independent variables to evaluate
RV function by echocardiogram. Although the pulmonary artery pressure is lower in MCT-treated rats, and RV dysfunction is similar in both models,
MCT-treated rats exhibit a higher mortality rate compared with the SU5416/hypoxia model (D). Rats treated with a dose of 160 mg/kg or higher develop liver
alterations consistent with hepatic venooocclusive disease [E, reproduced with permission of Frank Snow (19)]. Histological analysis of MCT-treated right
ventricles demonstrated a severe inflammatory infiltrate in the RV (F and G). A similar inflammatory infiltrate was present in the left ventricle of MCT-treated
rats (H, arrows) and was associated with medial hypertrophy of coronary arterioles (H, arrowhead) and marked perivascular fibrosis (I). Immunohistochemistry
reveals that the majority of the inflammatory infiltrates are prominently positive for the B cell marker CD20 (K), negative for CD68! (J), and identifies few CD8!
cells (L). These results are consistent with an MCT-induced lymphocytic myocarditis. SuHx, SU5416/hypoxia-exposed rats; mPAP, mean pulmonary arterial
pressure; RVID, right ventricular internal diameter.
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Figure 12. Both monocrotaline (MCT) and SU5416/hypoxia animals develop pulmonary
hypertension, however, MCT-treated rats present with a lower degree of pulmonary
hypertension compared with the SU5416/hypoxia model (A). Both models develop a
similar degree of right ventricular (RV) dysfunction assessed by increased RV internal
diameter (B) and decreased tricuspid annular planar systolic excursion (TAPSE, C), two
heart rate-independent variables to evaluate RV function by echocardiogram. Although
the pulmonary artery pressure is lower in MCT-treated rats, and RV dysfunction is
similar in both models, MCT-treated rats exhibit a higher mortality rate compared with
the SU5416/hypoxia model (D). Rats treated with a dose of 160 mg/kg or higher develop
liver alterations consistent with hepatic venooocclusive disease [E]. Histological analysis
of MCT-treated right ventricles demonstrated a severe inflammatory infiltrate in the RV
(F and G). A similar inflammatory infiltrate was present in the left ventricle of MCTtreated rats (H, arrows) and was associated with medial hypertrophy of coronary
arterioles (H, arrowhead) and marked perivascular fibrosis (I). Immunohistochemistry
reveals that the majority of the inflammatory infiltrates are prominently positive for the B
cell marker CD20 (K), negative for CD68+ (J), and identifies few CD8+ cells (L). These
results are consistent with an MCT-induced lymphocytic myocarditis. SuHx,
SU5416/hypoxia-exposed rats; mPAP, mean pulmonary arterial pressure; RVID, right
ventricular internal diameter.
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tolerate higher levels of RV afterload – remains undetermined but should be considered.
Indeed, as mentioned in Chapter 3, although inflammatory cells have been found present
in patients with pulmonary hypertension associated with systemic sclerosis(165), a
mechanistic role for these cells is still incomplete and, conversely, they could serve as
confounders for the development of RV failure.
4.2.3 Limitations of the Monocrotaline-Injury Model of PAH: Do rats die with PH
or from PH?
As reviewed in the Chapter the monocrotaline rat model of pulmonary hypertension
remains a model favored by many investigators, continues to impact preclinical PAH
research (215), and a significant amount of time and funding continues to be invested in
testing new drugs in this model (245). We are skeptical and of the opinion that the MCT
model is not an appropriate model of human severe PH. Pulmonary vasoconstriction
seems to be an important mechanistic component of the MCT-model (37, 143, 162, 202),
and while that is shared in a certain subpopulation of patients with PAH (those
documenting a large vasoconstriction component), pulmonary interstitial edema,
myocarditis and hepatic venoocclusive disease (not to mention renal alterations (123)),
which are part of the monocrotaline syndrome, are certainly not associated with the
human forms of severe PAH (renal insufficiency is however a late manifestation (205)).
Whereas the “two hits” model of monocrotaline/pneumonectomy can reproduce the
pertinent pulmonary vascular pathology of human PAH, the other components of the
monocrotaline syndrome may be cofounding. Also importantly, in contrast to the
SU5416/hypoxia model (225), a very large number of drugs and compounds have either
prevented or improved pulmonary hypertension in the MCT-alone (single-hit) model.
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Paradoxically the animals, when untreated, die from undetermined causes. Hence the
question: do MCT-treated rats die with PH or from PH? As a preclinical model of severe
PAH, the MCT-alone model may be misleading as the particular syndrome associated
with the development of PH (after a single injection of MCT) and the successful
treatment of the MCT syndrome with practically any drug investigated (215), may have
little in common with human forms of severe PH.
4.3 Pulmonary artery banding: A model for Adaptive (functional) Right Ventricular
Hypertrophy
Many researchers have utilized the pulmonary artery banding (PAB) model to study the
effects of mechanically-induced pressure-overload of RV. As mentioned in Chapter 3,
increasing impedance, and therefore the afterload of the RV, by means of a band around
the pulmonary artery would theoretically lead to RV dysfunction and eventually RV
failure. Indeed, the transverse aortic constriction model is commonly used to reproduce
systemic hypertension and left ventricular failure(12). Because the RV seems to adapt to
increased pressure overload in a certain group of patients (mainly patients with
Eisenmnger Syndrome, as studied in Chapter 3), Bogaard et al. (25) revisited the rat PAB
model and compared the measurements obtained with the SU5416/hypoxia model, a
model of severe pulmonary hypertension and RVF (see below). Interestingly, and in
contrast to what would be expected, the PAB rats were able to tolerate high RV systolic
pressures for a remarkably long time and TAPSE (tricuspid annular plannar systolic
excursion), a heart-rate independent measurement of RV longitudinal contractility
commonly used to evaluate RV function in patients with PAH, was similar to that of
control rat RVs (3.25mm in PAB versus 3.46 in controls). In order to explain why the RV
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of PAB rats was more ‘resilient’, microarray-based gene expression analysis of the
compensated rat RVH was performed. This analysis allowed the characterization of a
‘RV failure transcriptional signature’(55). Following PAB surgery, rats showed an
increased expression of IGF-1 (insulin-like growth factor-1) mRNA, normal levels of
phosphorylated Akt and VEGF protein levels, as well as and an increased amount of
apelin (another pro-angiogenic factor) when compared to RV tissues from rats with RVF
(SU5416/hypoxia rats)(25). These results were in line with what Faber et al. reported
when evaluating right and left ventricular function in PAB rat(64). The authors
demonstrated that 6 weeks of pressure overload resulted in enhanced baseline RV
contractility while LV baseline contractility remained unaffected. In contrast, Fang,
Archer and collaborators showed that 4 weeks after PAB, the cardiac output and treadmill
distance were significantly reduced in the PAB vs. control animals(65). Possible
explanations for this discrepancy could be the differences in pulmonary artery lumen
reduction and the time allowed for RV adaptation.
Another interesting feature are the changes in the RV when compared to the LV
subjected to pressure-overload in rodents. The Stanford pediatric cardiology group
performed PAB in mice and then analyzed the RV and LV tissues with mRNA
microarrays(234). Animals with moderate pulmonary stenosis had a 50% survival of >50
days. Importantly, the right ventricular end-diastolic pressure increased 6 hours
postoperatively in mice with severe stenosis, but remained within the normal range in the
animals with moderate outflow tract stenosis. Furthermore, the authors demonstrated a
differential expression of genes between the pressure-overloaded right ventricles when
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compared to the left counterparts. Altogether, the published data suggest that PAB can be
used as a model of RV pressure-overload with associated adaptive hypertrophy.
4.4 The SU5416/hypoxia rat model of pulmonary arterial hypertension: A brief
summary
The combined VEGF receptor 1 (Flt) and 2 (KDR) blocker, SU5416, was one of the first
agents discovered by screening for growth inhibitory activity of cultured endothelial cells
incubated with the potent angiogenic VEGF ligand (68). Kindly provided by Dr. Peter
Hirth (Sugen, South San Francisco, CA), for preclinical studies, SU5416 was tested with
the hypothesis that inhibition of VEGF signaling would result in pulmonary emphysema.
Indeed, a single subcutaneous injection of 20 mg/kg of SU5416 caused airspace
enlargement and mild PH in adult rats (115). Unexpectedly, rats injected with SU5416
(20 mg/kg) were exposed to chronic hypoxia in a hypobaric chamber, as an attempt to
worsen the airspace enlargement. The results of these experiments were published in
2001 (223). Surprisingly, the combination of SU5416 and chronic hypoxia (hereafter
SUHx) resulted in the development of severe PAH which was not reversible when the
animals were returned to Denver altitude (223) or in later experiments to sea level
(Figure 13) (25). The PH was associated with angioobliterative pulmonary lesions which
were preventable by treating the animals concomitantly with a pan-caspase inhibitor,
indicating that apoptosis was necessary for the development of pulmonary vascular
lesions (223). This rat model has served as a model for preclinical drug studies designed
to examine whether the PH and pulmonary vascular disease in the SuHx rats could be
reversed once established.
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Figure 13. Comparison between a normal lung vessel and the vascular lesions present in
the SU5416/hypoxia rat model of severe pulmonary arterial hypertension.

Supplemental Figure 1 #
Normal

200#μm#

50#μm#

F
RVSP (mmHg)

A

#

G
TAPSE (mm)

SuHx

50#μm#

200#μm#

50

H

PAB

200#μm#

50#μm#

72	
  

SuHx

PAB

#
#

4
3
2
1
Controls

SuHx

#

0.8

PAB

*

0.6
0.4
0.2
0.0

	
  

Controls

5

0

RV/LV+S

D
C

NS

100

0

B

#

150

Controls

SuHx

PAB

Figure 13. Microphotographs showing the histological differences in the lung
vasculature between controls (A), SuHx (B) and Pulmonary Artery Banding (PAB) (C).
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Because in this rat model the PH is severe, is accompanied by plexiform-like lessions and
is largely refractory to treatment, it was concluded that the SUHx rat model of
angioobliterative severe PH had a number of features which resembled the human
disease. Moreover, Abe et al has shown the histopathological similarities of the SUHx
lung vascular lesions in comparison to the plexiform lesions in human disease (1). In
addition to severe PH, rats treated with SU5416 and exposed to chronic hypoxia also
develop severe RV failure characterized by a cardiac output reduction, decreased TAPSE,
increased RV diastolic diameter, capillary rarefaction, RV fibrosis and cardiomyocyte
apoptosis (25, 27, 162).
The SUHx model has been modified to uncover immunological mechanisms in the
pathobiology of severe PAH. We have shown that treatment of athymic rats with SU5416
is sufficient to cause severe angioobliterative PAH— indicating that hypoxia is not
necessary (224), and that early immune reconstitution with rat regulatory T lymphocytes
prevents the development of severe PAH (222, 224). For further information regarding
the SuHx model the reader is referred to ((25, 194, 195, 223)).
4.5 Mouse Models of Right Ventricular Failure: Problems and Prospects
The advent and development of genetically modified mice, as tools to dissect cellular and
molecular signaling pathways, created an understandable desire to generate mouse
models for PH studies. In recent years a considerable number of transgenic mice have
been generated in order to investigate mechanisms of pulmonary hypertension (See Ref
(82)). In particular, the report of associations between mutations in the BMPR2 gene with
both familiar and idiopathic forms of pulmonary arterial hypertension (PAH) (101, 137,
157, 218), led to multiple attempts to generate novel animal models of PAH. In addition
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to BMPR2 knock out (KO) mice, researchers have targeted other genes suspected to be
involved in the pathogenesis of PAH. Very likely the transgenic mouse studies have
strongly influenced the way we think of the pathogenesis of PAH and helped shift the
early mechanical concepts of pressure – and flow – dependency, towards disease models
built on cell-to-cell interactions, immune dysregulation, metabolic changes and abnormal
cell phenotypes (50, 149, 181, 183, 224, 251, 262). However, although somewhat useful
for the study of lung vascular remodeling, mice exhibit multiple limitations as a model of
right ventricular failure.
RV hypertrophy is easy to measure by separating the RV-free wall from the rest of the
heart (70). In rats, the RVSP is strongly correlated with the RV/LV+S (162) suggesting
that the RV responds to an increased afterload with a corresponding degree of
hypertrophy. Rat models of PAH – such as the SU5416/hypoxia and monocrotalineinjury models – generate robust RV hypertrophy (mean RV/LV+S 0.67-0.76) (25, 80). In
contrast to rat models, only mice overexpressing interleukin-6 seem to develop a
comparable degree of hypertrophy (average RV/LV+S 0.69) and pulmonary hypertension
(214). When plotting data extracted from the reviewed mouse PH studies (Figure 14BD), there seems to be an “uncoupling” between RVSP and RV/LV+S for the majority of
PH-mouse studies, even after hypoxia exposure. For example, Xu et al (261)
demonstrated that mice lacking the adenosine A2A receptor develop spontaneous PH
(RVSP 39 mmHg), however the RV/LV+S was only 0.26, a value that is within normal
limits for C57BL6/J WT mice (219). In contrast, Chen and collaborators (39) reported
that mice overexpressing
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Figure 14. Brief analysis of the hemodynamics and right ventricular hypertrophy of mice
models of pulmonary hypertension
Review
MOUSE MODELS OF PULMONARY HYPERTENSION

L981

was ubiquitous and severe, the RVSP was not elevated (range
21–29 mmHg) and there were no signs of right heart hypertrophy. Thus, at least in the mouse, severe pulmonary vascular
remodeling does not necessarily cause severe pulmonary arterial hypertension.
Right Ventricular Failure in Transgenic Mouse Models of
Pulmonary Hypertension
RVF is the leading cause of death and the main determinant
of survival in patients with PAH (7, 83). Intriguingly, whereas
the mechanisms of pulmonary vascular remodeling have been
extensively studied in both mouse and rat models of PAH, the
mechanisms underlying RVF remain largely elusive (9, 110).
RV hypertrophy
is easy to measure by separating the RV free
	
  

wall from the rest of the heart (28). In rats, RVSP strongly
correlates with the RV/LV!S (72), suggesting that the RV
responds to an increased afterload with a corresponding degree
of hypertrophy. Rat models of PAH, such as the SU5416/
hypoxia and monocrotaline-injury models, generate robust RV
hypertrophy (mean RV/LV!S 0.67– 0.76) (11, 35). In contrast
to rat models, only the IL6-OE mice seem to develop a
comparable degree of hypertrophy (average RV/LV!S 0.69)
and PH (94). When plotting data extracted from the reviewed
mouse PH studies (Fig. 1, B–D), there seems to be an “uncoupling” between RVSP and RV/LV!S for the majority of PH
mouse studies, even after hypoxia exposure. For example, Xu
et al. (122) demonstrated that mice lacking the adenosine A2A
receptor develop spontaneous PH (RVSP 39 mmHg); however,
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Fig. 1. A: C57BL6 mouse. B: correlation between right ventricular systolic pressure (RVSP) and right ventricle (RV) to left ventricle (LV) plus septum (S) ratio
(RV/LV!S) in mouse pulmonary hypertension (PH) models exposed to normoxia and hypoxia, compared with the combination of SU5416 and chronic hypoxia
(SuHx) and monocrotaline (MCT)-injured rat models. C: correlation between RVSP and RV/LV!S in mouse models exposed to normoxia. Pearson coefficient
0.32, P " 0.150. D: correlation between RVSP and RV/LV!S in mouse models exposed to hypoxia. If all mouse models are included, the Pearson coefficient
is 0.82, P " 0.0008. However, the correlation seems to be driven by an outlier, the IL6-OE mice (red dot). Thus, if the latter is not included in the statistical
calculations, the coefficient becomes nonsignificant (r " 0.58, P " 0.057) (E). F: hematoxylin and eosin (HE)-stained lung section of a pulmonary vessel
obtained from wild-type C57BL6 mice chronically exposed to ovalbumin. The mice develop severe pulmonary arterial muscularization without pulmonary
hypertension. The vascular remodeling does not involve endothelial cell proliferation (G; brown staining is smooth muscle actin and blue is von Willebrand
factor). F and G are reprinted from Daley et al. (2008), doi:10.1084/jem.20071008.

Figure 14 A: C57BL6 mouse. B: correlation between right ventricular systolic pressure
(RVSP) and right ventricle (RV) to left ventricle (LV) plus septum (S) ratio (RV/LV+S)
in mouse pulmonary hypertension (PH) models exposed to normoxia and hypoxia,
compared with the combination of SU5416 and chronic hypoxia (SuHx) and
monocrotaline (MCT)-injured rat models. C: correlation between RVSP and RV/LV+S in
mouse models exposed to normoxia. Pearson coefficient 0.32, P <0.150. D: correlation
between RVSP and RV/LV+S in mouse models exposed to hypoxia. If all mouse models
are included, the Pearson coefficient is 0.82, P < 0.0008. However, the correlation seems
to be driven by an outlier, the IL6-OE mice (red dot). Thus, if the latter is not included in
the statistical calculations, the coefficient becomes nonsignificant (r =0.58, P < 0.057)
(E). F: hematoxylin and eosin (HE)-stained lung section of a pulmonary vessel obtained
from wild-type C57BL6 mice chronically exposed to ovalbumin. The mice develop
severe pulmonary arterial muscularization without pulmonary hypertension. The vascular
remodeling does not involve endothelial cell proliferation (G; brown staining is smooth
muscle actin and blue is von Willebrand factor). F and G are reprinted from Daley et al.
(2008), doi:10.1084/jem.20071008
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connective tissue growth factor (CTGF) generate modest PH (average RVSP 22 mmHg
versus 10 mmHg in WT controls) but develop significant RV hypertrophy (RV/LV+S
0.42).
Three of the published mouse models of PH have provided unpredicted and puzzling
results which ought to be followed-up to better understand the integrated response of the
lung circulation/heart axis, in the setting of PAH and chronic hemodynamic stress. For
instance, Daley et al (50) reported very pronounced pulmonary artery muscularization,
but no RV hypertrophy. In contrast, the studies of Shifren et al (206) demonstrate that
mice lacking elastin develop impressive elevation of RVSP without RV hypertrophy.
Finally, in hemeoxygenase-1 knock out mice, Yet et al demonstrated that after chronic
hypoxia exposure, mice did not develop RV hypertrophy, but developed RV dilatation
(264). All together, these last three studies exemplify that in mice: 1) Severe
muscularization does not necessarily indicate pulmonary hypertension 2) PH is not
always translated into RV hypertrophy 3) RV remodeling could happen in the absence of
PH. Whether increased pulmonary arterial pressure and right ventricular remodeling are
two mechanistically distinct processes which are usually coupled in PAH remains to be
investigated.
4.6 Summary and Conclusions
Animal models serve as a powerful tool to evaluate human disease. Unfortunately, none
of the current models is perfect and each one of the presented in this Chapter offers
unique, and perhaps, complementary features for the researcher interested in studying RV
failure. The pulmonary artery banding model in rats and mice could offer tremendous
opportunities to study genes or proteins required for RV adaptation to chronic pressure
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overload. Conversely, models of established RV failure such as monocrotaline or
SU5416/hypoxia have been used to describe the mechanisms potentially involved in the
transition from adaptive to maladaptive RV hypertrophy and can therefore serve to
identify and study key molecular players involved in the reversal of RV failure.
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Chapter 5: Methodology and Statistical Analysis

Segments of this chapter have been previously published in:

Gomez-Arroyo J, et al. Metabolic gene remodeling and mitochondrial dysfunction in
failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ
Heart Fail. 2013 Jan 1;6(1):136–144.

	
  

80	
  

CHAPTER 5

5. 1 Generation of Animal Models
5.1.2 SU5416/Hypoxia model
Male Sprague-Dawley rats (weight 200-250 g) received a single injection of SU5416
suspended in 0.5% (w/v) carboxymethylcellulose sodium, 0.9% (w/v) sodium chloride,
0.4% (w/v) polysorbate 80, and 0.9% (v/v) benzyl alcohol in deionized water, according
to our protocol and previously published literature(79, 223), at a dose of 20 mg/kg
subcutaneously and were exposed in a hypoxia (nitrogen dilution) chamber simulating an
approximate altitude of 5000 m. for 4 weeks. As previously described, the RV in the
SuHx rat model responds to pulmonary hypertension with a robust degree of
hypertrophy, followed by dysfunction and failure(162). The RV in this rat model is
characterized by fibrosis, capillary rarefaction and cardiomyocyte apoptosis(25), which
are associated with decreased cardiac output, markedly dilated RV and decreased
exercise capacity(26). Also, as previously described, the SuHx RV dysfunction model
reproduces some features of human RV dysfunction, such as paradoxical septal
movement and RV dilatation.
5.1.2 Pulmonary artery banding
Male Sprague-Dawley rats (weight 180-200 g) were anesthetized with isoflurane
inhalation (5% and 2%, respectively, in oxygen-enriched room air). After intubation, the
animals are mechanically ventilated with the use of a volume-controlled respirator.
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Positive endexpiratory pressure was maintained at 4 cmH2O. A left thoracotomy as
performed, where the pulmonary artery was carefully dissected free from the aorta. A silk
thread was then positioned underneath the pulmonary artery, while we also placed an 8gauge needle is placed alongside the pulmonary artery. A suture was tied tightly around
the needle, and the needle rapidly removed to produce a fixed constricted opening in the
lumen equal to the diameter of the needle. After the banding, the thorax was closed in
layers, and postoperative pain relief was obtained by applying buprenorphine (15µg/kg
s.c.). For more information about the procedure please refeer to Bogaard, et at.
Circulation 2009 (25). The PAB rats were sacrificed to collect organs 6 weeks after the
surgery, to allow for significant hypertrophy as reported by Bogaard et al(24, 25). As a
model of strictly mechanical RV pressure overload, the PAB rat model demonstrates
preserved RV function despite generating significantly high RV afterload and
hypertrophy(24, 25) (See Chapter 4). Thus, the PAB-model was utilized as a model of
non-dysfunctional RV hypertrophy.
5.2 Human samples
Human RV tissue samples were obtained from 4 patients diagnosed with PAH and RVF
that underwent cardiac transplantation. All human samples were kindly donated by the
Bosch Institute, University of Sydney, Sydney, Australia. Control RV samples were
obtained from a normal donor heart, carefully matching age and gender. Clinical
information regarding the human samples can be found Table 3.
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Table 3. Demographic and clinical information of patients with right ventricular
dysfunction and pulmonary hypertension
Patient

Age

Control

42

Female

Gender

I

NYHA

Clinical

Class

Data

Brain death due to
subarachnoid
hemorrhage. No
previous cardiac or
pulmonary disease.

EMS 1

21 Female

II

Large VSD and pulmonary hypertension.

EMS 2

46 Female

IV

Large VSD and pulmonary hypertension.

PAH 1

38 Female

IV

Familiar IPAH, mean pulmonary pressure
80 mmHg, wedge pressure 10, cardiac
index 1.76. Negative vasoreactive test. No
specific PAH treatment.
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Table 3. Demographic and clinical information of patients with right ventricular
dysfunction and pulmonary hypertension. Heart samples from free RV wall were
obtained after cardiac transplantation, immediately frozen and stored. NYHA = New York
Heart Association Functional Classification at the moment of cardiac transplantation;
EMS = Eisenmenger’s Syndrome; IPAH = Idiopathic Pulmonary Arterial Hypertension;
VSD = Ventriculoseptal defect
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5. 3 Echocardiography
Doppler echocardiography was performed using the Vevo770 imaging system
(VisualSonics, Toronto, Canada) directly after the hypoxic exposure (baseline) and again
4 weeks later after treatment. Superficial anesthesia with ketamine/xylazine was used to
obtain two-dimensional, M-mode and Doppler imaging in both long axis and short-axis
views, using a 30-MHz probe. Measurements were made of the RV inner diameter in
diastole (RVID; long axis) and tricuspid annular plane systolic excursion (TAPSE; long
axis). The presence of pulmonary hypertension before treatment was evaluated by
measuring the pulmonary artery acceleration time and mid-systolic notching with pulsedwave Doppler recordings, as previously reported (235).
5.4 Hemodynamic measurements
Four weeks after SU5416 administration or four weeks after the first dose of carvedilol
(eight weeks after SU5416 injection), hemodynamic measurements were made using a
4.5 mm conductance catheter (Millar Instruments, Houston, TX) and the Powerlab data
acquisition system (AD Instruments, Colorado Springs, CO). The rats were anesthetized
with an intramuscular injection of ketamine at a dose of 100mg/kg and xylazine 15
mg/kg. Rats were then were intubated through tracheotomy and placed in a supine
position. After a median sternotomy the RV outflow tract was punctured with a 23G
needle and the catheter was introduced ante grade to measure pulmonary artery pressures.
5.5. Tissue preparation for molecular analysis
Upon sacrifice, the right lung and the total heart were removed. The RV was carefully
dissected from the rest of the heart to measure the RV/LV+S. RV weight over left
ventricle and septum weight (LV/+S) weight is the standard assessment for hypertrophy,
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as previously reported(25, 79, 82). After dissection the lung, RV and LV+S tissues were
frozen with liquid nitrogen until the isolation of mRNA and protein was performed. The
left lung was inflated with 0.5% low-melting agarose at a constant pressure of 25cm H2O,
fixed in 10% formalin for 48 hours and used for histological evaluation of the lungs and
IHC analysis, as reported previously(25, 109).
5.6 Gene expression studies
Using the FastPrep®- 24 instrument (MP Biomedicals, Solon, OH), 25mg of RV or LV
or Lung tissue were homogenized with Triazol® (Qiagen, Valencia, CA) in Lysing
Matrix D impact-resistant 2ml tubes (MP Biomedicals, Solon, OH). mRNA was carefully
isolated using a RNeasy (Qiagen, Valencia, CA) isolation kit according to manufacturers
protocol. Total RNA (1 µg) was reverse transcribed into first complimentary DNA
(cDNA) using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA). First strand cDNA was diluted 10 times and RT-QPCR performed
using Power SYBR® Green PCR Master Mix (Applied Biosystems) along with murine
specific primers (Table 4).
All PCR reactions were performed with a LightCycler480 PCR system (Roche
Diagnostics, Meylan, France). The cycling parameters were the following: initial
denaturation at 95°C for 15 min, followed by 50 cycles of denaturation at 94°C for 15s,
annealing at 55°C for 15 s, and extension at 72°C for 15 s. The α-actinin 1 and 18 S
genes were used as the reference gene for mRNA relative quantification. All gene
expression results were normalized to controls, and expressed as mean± SEM unless
otherwise specified.
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5.7 Western Blotting
Whole cell lysate from isolated right ventricle was prepared using RIPA (RadioImmunoprecipitation Assay) buffer (Sigma, St. Louis, MO), and the protein
concentration was determined using BioRad Protein DC Protein Assay (BioRad,
Hercules, CA). Thirty micrograms of whole cellular protein per lane was separated by
SDS-PAGE with a 4-12% Bis-Tris NUPAGE gel (MES SDS running buffer) and blotted
onto a PVDF membrane. The membrane was incubated with blocking buffer (5% non-fat
dry milk/PBS 0.1%/Tween 20) at room temperature for 1 hour. The membrane was then
probed with the primary antibodies diluted in blocking buffer overnight at 4˚C.
Subsequently, membranes were incubated with horseradish peroxidase-conjugated antimouse or anti-rabbit antibody diluted 1:1000 in blocking buffer. Blots were developed
with ECL (PerkinElmer, Waltham, MA) on GeneMate Blue Basic Autorad Films
(BioExpress, Kaysville, UT). Blots were scanned and densitometry analysis was done
with ImageJ (National Institutes of Health 1997-2011, Bethesda, MD;
http://imagej.nih.gov/ij). Rabbit anti-PGC1α antibody was acquired from Cell Signaling
Technology, Inc., Beverly, MA. Rabbit anti-ACADM and ACADVL antibody were
acquired from Abcam plc, Cambridge, MA. Rabbit anti-PPARα antibody, ND4L and
CytB were purchased from Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and rabbit
anti-estrogen related receptor alpha (EPR46Y) was purchased from Millipore, Billerica,
MA.
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Table 4. List of Primers Used
NCBI
Gene

Gene

Forward Sequence

Reverse Sequence

Ref.
α-actinin 1 81634

ACADM

ACADVL

ACADS

ACSL1

CD36

COUP-

	
  

24158

25363

64304

25288

29184

11398

5'

5'

TCAGTTGGAAGGATGGT

AAGGCTGTGTTCAGGTTTGT

CTTG 3'

G 3'

5'

5'

GACGGAGCAGCAGAAAG

CTTGATGAGAGGGAACGGG

AGTT 3'

TA 3'

5'

5'

AAGTGAATGACCCTGCC

ATGCCCCCAGTTCTTTGAGT

AAGA 3'

C 3'

5'

5'

CTGGATTGTGCCGTGAA

GCTTGAACTGGATGTTTTGG

GTAC 3'

A 3'

5'

5'

GGGTACTACTGAGGGTG

CTCTGGAAGCCATCGTACAT

TCCG 3'

C 3'

5'

5'

GTTATTGGTGCTGTCCTG

CCGTTTTCACCCAGTTTTTG

GCT 3'

A 3'

5'

5'
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TF1

CPT-1α

CPT-1β

CPT-2

CS

ERRα

ERRγ

GLUT-1

	
  

4

CTTTTGCTTCGTCTCCCTT ATGGGGGTTTTACCTACCAA
CC 3'

A 3'

5'

5'

GGCATGATCGCAAAGAT

GCCACCCAGAGCCCTGTAC

CAGT 3'

CA 3'

5'

5'

AAGAACACGAGCCAACA

TACCATACCCAGTGCCATCA

AGCA 3'

C 3'

5'

5'

GCTGCCTATCCCTAAACT

AACGCTTCTGTTCTCCTGAA

TGA 3'

C 3'

17058

5'

5'

7

CTGAGTGCCAGAAACTG

GTGAGAGCCAAGAGACCTG

CTAC 3'

TT 3'

29370

5'

5'

1

CACAAGGAGGAGGAGGA AGGCGTTTGGGTAGAGAGC

25757

25756

25413

TGG 3'

T 3'

36089

5'

5'

6

TCCCCAGACCAAGTGTG

AGTGATACCCAGAGGCGAT

AATA 3'

GT 3'

5'

5'

TTCCTGCTCATCAATCGT

ACCCTCTTCTTTCATCTCCT

AAC 3'

G 3'

24778
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Hexokinas

25058

e1

Hexokinas

25059

e2

IDH1

24479

5'

5'

TGATGGAGGTGAAGAAG

GGCAGCATTTTGACAGTAG

AGGC 3'

CT 3'

5'

5'

GAAGATGATTAGCGGGA

TAAGGAGTTCTGGGCTGAG

TGTA 3'

TT 3'

5'

5'

CACACAGTTCCTTCCAAA GCGTCCATCATACTTCTTCA

PDHb

PDK-1

PGC-1α

PPAR-α

PPAR-δ

	
  

TGG 3'

G 3'

28995

5'

5'

0

GCTGAGATTTGTGCGAG

CGTAAGGCATAGGGACATC

AATT 3'

AG 3'

5'

5'

CGAAACAGACATCATAA

GAATATGAGGATGTGCTGG

TGTG 3'

TT 3'

5'

5'

ACCCCAGAGTCACCAAA

GCAGTTCCAGAGAGTTCCA

TGA 3'

C 3'

5'

5'

GGTCCTCTGGTTGTCCCC

GTGAGTTACGCCCAAATGC

TT 3'

A 3'

5'

5'

AACTTCAGCAGCCTCTTC

ACCAGCAGTCCGTCTTTGTT

89813

83516

25747

25682
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PPAR-γ

SP-1

	
  

25664

24790

CTC 3'

G 3'

5'

5'

CGGTTGATTTCTCCAGCA

TCGCACTTTGGTATTCTTGG

TT 3'

3'

5'

5'

AGCAGCAATACCACCCT

GACAGTTGAGCAGCATTCA

TACA 3'

CA 3'
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5.8 Isolation of mitochondria
Isolation of a single population of cardiac mitochondria was conducted as described
previously (217), except that approximately 100 mg of right ventricle tissue were used.
Briefly, tissue was washed in a modified Chappell-Perry (CP) buffer (buffer CP1 at pH
7.4: 100 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM MgSO4⋅7H2O, 1 mM ATP), dried
with Whatman filter paper, weighed, minced and homogenized in CP1 buffer using a
polytron tissue blender (Kinematica, Bohemia, NY). The homogenate was supplemented
with 5 mg/g (wet weight) trypsin (#T0303, Sigma-Aldrich), incubated with stirring for 15
min at 4 oC followed by addition of 3 ml of CP2 buffer (CP1 buffer containing 0.2% BSA
(#A7030, Sigma-Aldrich) to attenuate trypsin activity). Digested tissue was further
homogenized by two strokes using a digital steady-stirring tight Teflon pestle/glass tube
homogenizer set at 600 rpm (Fisher Scientific, Pittsburgh, PA). Undigested tissue and
heavier cell fractions in the remaining volume were pelleted by centrifugation at speed
500g for 10 min at 4 oC. The mitochondria-containing supernatant was centrifuged at
3000g for 10 min at 4 oC. The mitochondrial pellet was washed with 1 ml of KME buffer,
pH 7.4 (100 mM KCl, 50 mM MOPS, 0.5 mM EGTA). Mitochondria were re-suspended
in KME and used within 4 h after isolation or frozen. The protein concentration was
measured by Lowry (134) using BSA as a standard and sodium deoxycholate as a
detergent.
5.9 Mitochondrial oxidative phosphorylation
Oxygen consumption by intact mitochondria was measured using a Clark-type oxygen
electrode (Strathkelvin Instruments, North Lanarkshire, UK) at 30 oC in respiration buffer
at pH 7.4 (80 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM KH2PO4, 1 mg/ml defatted
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BSA) as previously described (38, 132). Briefly, substrates for complex I (20 mM
glutamate), complex II (20 mM succinate with 7.5 µM rotenone), and complex IV (1 mM
N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD)/20 mM L- ascorbate with 7.5 µM
rotenone) were used and state 3 (0.2 mM ADP-stimulated), state 4 (ADP-limited)
respiration, respiratory control ratio (RCR), maximal rate of state 3 respiration (2 mM
ADP), and ADP/O ratio were determined.
5.10 Chromatography Electrospray Ionization Tandem Mass Spectrometry
Eicosanoids were analyzed from frozen heart samples as follows. Briefly the frozen heart
tissues were thawed on ice and homogenized using an Omni TH tissue homogenizer to
obtain a 10% (w/v) solution in PBS. 200 µl of the solution thus obtained was diluted 1ml
of LCMS grade ethanol containing 10 ng of each internal standard and 0.05% BHT. The
internal standards used were, (d4) 6k PGF1α, (d4) 8-iso PGF2α, (d4) PGF2α, (d4) PGE2,
(d4) PGD2, (d4) LTB4, (d4) TXB2, (d4) LTC4, (d5) LTD4, (d5) LTE4, (d8) 5hydroxyeicosatetranoic acid (5HETE), (d8) 15-hydroxyeicosatetranoic acid (15HETE),
(d8) 14,15 epoxyeicosatrienoic acid, (d8) Arachidonic Acid, and (d5) Eicosapentaenoic
acid. The mixture thus obtained was agitated to homogeneity using a bath sonicator and
the resultant suspension was incubated in the dark at 4 0C for 5 hours with periodic
sonication. Following incubation, the insoluble fraction was precipitated by centrifuging
at 6000g for 20 minutes and the supernatant was transferred into a new glass tube. This
supernatant was dried under vacuum followed by reconstitution in 100 µl of 50:50
EtOH:dH2O for quantitation via LC/MS/MS. A 30 minute reversed-phase LC method
utilizing a Kinetex C18 column (150 x 2.1mm, 1.7µm) was used to separate the
eicosanoids at a flow rate of 200µl/min at 50°C. The column was equilibrated with 100%
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Solvent A [acetonitrile:water:formic acid (10:90:0.02, v/v/v)] for five minutes and then
10 µl of sample was injected. 100% Solvent A was used for the first minute of
elution. Solvent B [acetonitrile:isopropanol (50:50, v/v)] was increased in a linear
gradient to 25% Solvent B to 3 minutes, to 45% until 11 minutes, to 60% until 13
minutes, to 75% until 18 minutes, and to 100% until 20 minutes. 100% Solvent B was
held until 25 minutes, then was decreased to 0% in a linear gradient until 26 minutes, and
then held until 30 minutes. The eicosanoids were analyzed using a hybrid triple
quadrapole linear ion trap mass spectrometer (QTRAP5500® ABSciex) via multiplereaction monitoring in negative-ion mode. Eicosanoids were monitored using precursor
→ product MRM pairs. The mass spectrometer parameters used were: curtain gas: 30;
CAD: High; ion spray voltage: -3500V; temperature: 500°C; Gas 1: 40; Gas 2: 60;
declustering potential, collision energy, and collision cell exit potential vary per
transition.
5.11 Statistical analysis
Differences between groups were assessed with one-way or two-way ANOVA or
Kruskall-Wallis tests. Bonferroni’s and Dunn’s post-hoc tests were used to assess
significant differences between groups. A p-value < 0.05 was accepted as significant.
Correlation analysis was done with Spearman’s test. Results are reported as means±SEM,
or fold-change mean±SEM unless specified otherwise. Four-to-six rats were used per
group, unless otherwise specified. Statistical analysis was done with PASW V.18 (IBM,
Armonk, New York) and GraphPad Prism (La Jolla, CA).
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Chapter 6: Metabolic gene remodeling and mitochondrial dysfunction in failing
right ventricular hypertrophy secondary to pulmonary arterial hypertension

This entire chapter has been previously published in:

Gomez-Arroyo J, et al. Metabolic gene remodeling and mitochondrial dysfunction in
failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ
Heart Fail. 2013 Jan 1;6(1):136–144.
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CHAPTER 6

6.1 Introduction
As discussed in Chapter 2 and 3 pulmonary arterial hypertension (PAH) is a severe and
often rapidly progressive group of diseases which are characterized by a chronically and
frequently progressive increase in the right ventricular (RV) afterload(197). Increased RV
afterload is partially compensated by RV hypertrophy but eventually leads to RV
dysfunction (RVD), RV failure and untimely death, regardless of medical treatment(197).
Human and experimental chronic left heart dysfunction is characterized by decreased
oxidative metabolism(156), abnormal mitochondrial respiration(189) and impaired
mitochondrial biogenesis(113). These changes have in part been explained by a
deregulated expression of critical transcription factors such as the peroxisome
proliferator-activated receptor (PPAR) alpha(16), the estrogen-related receptor (ERR)
alpha(108) and the master regulator of oxidative metabolism, the PPAR-gamma
coactivator-1alpha (PGC-1α)(12).
Akin to left heart failure, it has been postulated that RVD is characterized by abnormal
energy metabolism(186, 231). Studies in animal models have demonstrated that RVD
exhibits an increased expression of glycolysis-related genes(54) and increased enzymatic
glycolysis rate(176). However, is largely unknown to what extent this switch in cardiac
bioenergetics (also known as metabolic remodeling(236)) involves changes in fatty acid
oxidation (FAO), whether metabolic remodeling is a response to chronic pressure
overload, or to what extent mitochondrial structure and function are also compromised in
RVD. Thus, we sought to 1) characterize the metabolic gene expression profile associated
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with RV dysfunction, 2) determine whether pressure overload is sufficient to explain
metabolic gene remodeling, 3) assess the structure and function of mitochondria in the
dysfunctional RV.
6.2 Results
6.2.1 RV dysfunction is characterized by a load-independent downregulation of
PGC-1α, PPAR-α and ERR-α.
Drake et al. have previously reported that dysfunctional RVs from SuHx-rats,
differentially express multiple gene signalling pathways when compared with nondysfunctional hypertrophied RVs(55). Importantly, we reported that RVD is associated
with gene expression changes that suggest an abnormal metabolism, with a particularly
strong signal relating to the peroxisome proliferator-activated receptor (PPAR) signaling
pathways. Therefore, as a first step, we measured the expression of PGC-1α, a direct
coactivator and master regulator of the PPAR family of transcription factors. PGC-1α
regulates oxidative metabolism and many aspects of mitochondrial biology(67).
Western blots of protein samples obtained from SuHx RV tissues showed a significantly
decreased amount of PGC-1α protein (Figure 15A). qPCR analysis revealed a significant
downregulation of PGC-1α mRNA levels (Figure 15B) indicating that the change in
PGC-1α expression also occurred on the transcription level. Decreased PGC-1α gene
expression was accompanied by a decreased expression of the ERR-α and PPAR-α genes
(Figure 15B). To evaluate whether pure mechanical RV pressure-overload was sufficient
to downregulate PGC-1α expression, we measured PGC-1α transcript levels in PAB-RV
tissues and found that the expression of PGC-1α, ERR-α and PPAR-α was not
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Figure 15. Gene and protein expression of PGC-1α, ERR-α and PPAR-α in SuHx RV
tissue and its relationship with RV function.
138

Circ Heart Fail
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Figure 1. A, Western blots on SU5416/
hypoxia (SuHx) right ventricular (RV) whole
tissue lysates show a downregulation of
peroxisome proliferator-activated receptor
(PPAR)-γ coactivator-1α (PGC-1α), estrogen-related receptor (ERR)-α, and PPAR-α
on the protein level. B, Quantitative reverse
transcription-polymerase chain reaction
mRNA expression analysis from right
ventricles of control, SuHx, and pulmonary
artery banding (PAB) animals. Compared
with controls and PAB, SuHx-RV tissue
exhibits decreased PGC-1α transcript
levels along with a decreased expression of
the nuclear receptors ERR-α and PPAR-α.
C, PGC-1α correlation with right ventricular
function (tricuspid annular plannar systolic excursion [TAPSE]). D, Quantitative
polymerase chain reaction analysis shows
no change in PGC-1α expression in RV and
left ventricle (LV) of SuHx rats at 1 week
after SuHx had been initiated. E, mRNA
expression of PGC-1α in SuHx lung tissue.
F, PGC-1α, ERR-α, and PPAR-α mRNA
transcript levels in human RV samples.
Data are shown in fold changes±SEM over
controls; **P<0.001; #P<0.0001.

	
  

PPAR family of transcription factors. PGC-1α regulates oxidative metabolism and many aspects of mitochondrial biology.21
Western blots of protein samples obtained from SuHx RV
tissues showed a significantly decreased amount of PGC-1α
protein (Figure 1A). Quantitative polymerase chain reaction analysis revealed a significant downregulation of PGC1α mRNA levels (Figure 1B), indicating that the change in
PGC-1α expression also occurred on the transcription level.
Decreased PGC-1α gene expression was accompanied by a
decreased expression of the ERR-α and PPAR-α genes (Figure
1B). To evaluate whether pure mechanical RV pressure-overload was sufficient to downregulate PGC-1α expression, we
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measured PGC-1α transcript levels in PAB-RV tissues
found that the expression of PGC-1α, ERR-α, and PPAR-α
was not significantly decreased in the nonfailing hypertrophied RVs of PAB rats, despite the high RV pressure and RV

correlated with the tricuspid annular plane systolic excursion,
a heart rate–independent variable of RV function.
We have described previously that SU5416 treatment
alone does not induce RVD and has a limited impact on gene
expression.20 However, because decreased expression of PGC1α could be a direct effect of the combination of SU5416 and
hypoxia rather than a consequence of RVD, we measured the
expression of PGC-1α 1 week after the SuHx protocol had
been initiated. At 1 week no RVD is present and, indeed, as
shown in Figure 1D, PGC-1α expression is not decreased
in the right ventricle or in the left ventricle. In addition, we
measured the expression of PGC-1α in rat lung tissues after
4 weeks of SuHx, a time point where plexiform-like lesions
have already formed, and we found a significant increase
in PGC-1α expression (Figure 1E). To further evaluate a
potential toxic effect of SU5416 in the setting of RV pressure

Figure 15. A, Western blots on SU5416/ hypoxia (SuHx) right ventricular (RV) whole
tissue lysates show a downregulation of peroxisome proliferator-activated receptor
(PPAR)- coactivator-1α (PGC-1α), estrogen-related receptor (ERR)-α, and PPAR-α on
the protein level. B, Quantitative reverse transcription-polymerase chain reaction mRNA
expression analysis from right ventricles of control, SuHx, and pulmonary artery banding
(PAB) animals. Compared with controls and PAB, SuHx-RV tissue exhibits decreased
PGC-1α transcript levels along with a decreased expression of the nuclear receptors
ERR-α and PPAR-α. C, PGC-1α correlation with right ventricular function (tricuspid
annular plannar systolic excursion [TAPSE]). D, Quantitative polymerase chain reaction
analysis shows no change in PGC-1α expression in RV and left ventricle (LV) of SuHx
rats at 1 week after SuHx had been initiated. E, mRNA expression of PGC-1α in SuHx
lung tissue. F, PGC-1α, ERR-α, and PPAR-α mRNA transcript levels in human RV
samples. Data are shown in fold changes±SEM over controls; **P<0.001; #P<0.0001.
Reproduced with permission from Gomez-Arroyo J, et al. Metabolic gene remodeling
and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to
pulmonary arterial hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–144.
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significantly decreased in the non-failing hypertrophied RVs of PAB rats, despite the
high RV pressure and RV hypertrophy (Figure 15B). Figures 15C and Figure 16 2A-B
illustrate that PGC-1α (R2=0.72, p=0.001), PPAR-α (R2=0.72, p=0.001) and ERR-α
(R2=0.76, p=0.002) transcript levels strongly correlated with the tricuspid annular plane
systolic excursion (TAPSE), a heart-rate independent variable of RV function.
We have previously described that SU5416 treatment alone does not induce RV
dysfunction and has a limited impact on gene expression(55). However, because
decreased expression of PGC-1α could be a direct effect of the combination of SU5416
and hypoxia rather than a consequence of RVD, we measured the expression of PGC-1α
at one week after the SuHx protocol had been initiated. At one week no RVD is present
and indeed, as shown in Figure15D, PGC-1α expression is not decreased in the RV or in
the LV. In addition, we measured the expression of PGC-1α in rat lung tissues after four
weeks of SuHx, a time-point where plexiform-like lesions have already formed, and we
found a significant increase in PGC-1α expression (Figure 15E). To further evaluate a
potential toxic effect of SU4516 in the setting of RV pressure overload, we examined the
RV gene expression of PAB animals exposed to SU4516 and found no change in the
PGC-1α, ERR-α or PPAR-α mRNA transcript levels (Figure 16C). Next, we measured
the expression of PGC-1α in LV tissue obtained from animals sacrificed four weeks after
initiation of the SuHx protocol. Although somewhat decreased, the SuHx-LV tissue did
not show a significant change in PGC-1α expression (Figure 16D). In the aggregate, the
data indicates that the decreased expression of PGC-1α is unlikely due to a toxic effect of
SU5416.
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Figure 16. Gene expression of PGC1α and other nuclear receptors involved in fatty
acid transition from fetal to adult hearts. Scatter-plot illustrating correlation between
TAPSE and mRNA expression of ERR-α (A) and PPAR-α (B). RT-PCR analysis reveals
no difference in the gene expression of PGC-1α, PPAR-α or ERR-α in the PAB model
after exposure to SU5416 (C) or in SuHx left ventricle tissue (D). E) mRNA transcript
levels of transcription factors other than PGC-1α that regulate cardiac energetics. N= 4-8
per group. Data are shown in fold-change mean ± SEM. * p=<0.05, #p=<0.001.
Reproduced with permission from Gomez-Arroyo J, et al. Metabolic gene remodeling
and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to
pulmonary arterial hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–144.
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Because nuclear receptors other than PGC-1α have been implicated in phenotypic
metabolic changes which occur during normal cardiac development, we decided to
evaluate the expression of the estrogen related receptor gamma (ERR-γ), and of the
transcription factors COUP-TF1 and SP1 (5, 191). QPCR analysis showed that the
expression of these transcription factors was not affected in dysfunctional RV tissues
(Figure 16E). Lastly, to examine whether the changed expression of the metabolic gene
pattern was also observed in human myocardium, we examined the gene expression of
PGC-1α, PPAR-α and ERR-α in RV tissue samples from patients with PAH. Indeed, we
found a comparable expression pattern in the human RV tissue as we had observed in the
SuHx RV rat tissue (Figure 15F).
6.2.2 Dysfunctional RV hypertrophy is characterized by decreased expression of
genes involved in fatty acid and glucose oxidation
Figure 17A illustrates that multiple PGC-1α/PPAR-α/ERR-α target genes encoding
critically important proteins, required for fatty acid transport into the cardiomyocytes and
into the mitochondria, were downregulated in the SuHx dysfunctional RVs. In addition,
the expression of genes encoding proteins required for beta-oxidation (ACADM,
ACADVL and ACADS) was decreased (Figure 17B). Western blot analysis confirmed
the decreased expression of ACADM and ACADVL in RVD (Figure 17C). Supporting
the observation of normal expression of PGC-1α/PPAR-α/ERR-α, non-failling
hypertrophied (PAB) RVs demonstrated a normal expression of ACADM and a
significantly increased expression of ACADS and ACADVL. These Acyl-CoA
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obtained from animals killed 4 weeks after initiation of the
SuHx protocol. Although somewhat decreased, the SuHx-LV
tissue did not show a significant change in PGC-1α expression
(Figure S2D). In the aggregate, the data indicate that the
decreased expression of PGC-1α is unlikely attributed to a
toxic effect of SU5416.
Because nuclear receptors other than PGC-1α have been
implicated in phenotypic metabolic changes that occur during
normal cardiac development, we decided to evaluate the expression of the ERR-γ and of the transcription factors COUP-TF1
and SP1.22,23 Quantitative polymerase chain reaction analysis
showed that the expression of these transcription factors was
not affected in dysfunctional RV tissues (Figure S2E). Lastly,
to examine whether the changed expression of the metabolic gene pattern was also observed in human myocardium,
we examined the gene expression of PGC-1α, PPAR-α, and
ERR-α in RV tissue samples from patients with PAH. Indeed,
we found a comparable expression pattern in the human RV tissue as we had observed in the SuHx RV 104	
  
rat tissue (Figure 1F).
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Figure 17. Gene and protein expression of PGC-1α target genes required for fatty
acid oxidation. mRNA levels of genes encod- ing key rate-limiting enzymes involved in
fatty acid transport into the cell (CD36) and transport into the mitochondria (ACSL1,
CPT1α, CPT1β, and CPT2) were decreased. B, Genes encoding a family of acyl-coenzyme A (CoA) dehydrogenases specific for fatty acid à-oxidation (ACADS, ACADM, and
ACADVL) also were downregulated
in dysfunctional SU5416/hypoxia (SuHx) right ventricles but significantly increased in
pulmonary artery banding (PAB) right ventricular (RV) tissue. C, Western blotting on
cytosolic protein extracts obtained from RV tissue lysate shows decreased protein
expression of ACADM and ACADVL in SuHx-RV tissue. D, Genes encoding key ratelimiting enzymes for aerobic glucose oxidation (Kreb cycle) were downregulated,
whereas genes encoding enzymes neces- sary for glycolysis were upregulated. Data are
shown in fold changes±SEM over con- trols; *P<0.01; #P<0.0001. Reproduced with
permission from Gomez-Arroyo J, et al. Metabolic gene remodeling and mitochondrial
dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial
hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–144.
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dehydrogenases are required to metabolize medium, short and long fatty acids,
respectively.
In accordance with our previous reports(55), dysfunctional RV hypertrophy in the SuHx
rats was characterized by increased expression of GLUT1 and Hexokinase-1; these two
genes play an important role in glycolysis (Figure 17D). In contrast, we found a
downregulation of genes that encode enzymes involved in aerobic glucose catabolism,
such as the genes encoding the Krebs cycle enzymes citrate synthase and isocitrate
dehydrogenase. Furthermore, the beta subunit of pyruvate dehydrogenase – an important
link between glycolysis and glucose oxidation – showed a 50% decreased mRNA
expression, whereas the gene expression of pyruvate dehydrogenase kinase (PDK-4), an
enzyme controlling pyruvate dehydrogenase activity was upregulated. Conversely, nonfailing hypertrophied PAB RVs exhibited a normal expression of glycolysis-related
genes, a significantly lower expression of PDK-4 and normal expression of isocitrate
dehydrogenase and citrate synthase (Figure 17D).
6.2.3 RVD is characterized by abnormal mitochondrial ultrastructure, impaired
mitochondrial respiration and abnormal mitochondrial biogenesis.
PGC-1α regulates mitochondrial biogenesis along with oxidative metabolism(67).
Therefore, we sought to explore abnormalities in mitochondrial biology. PGC-1α exerts
pleiotropic effects by direct coactivation of an array of nuclear and non-nuclear receptors
employed in the control of cellular metabolism(67). Among them, TFAM regulates
mitochondrial DNA replication and maintenance, and is required for cellular and
mitochondrial viability(118, 240). Associated with the decreased expression of PGC-1α,
SuHx-RVD tissue had a decreased expression of TFAM (Figure 18A). Because, reduced
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regulates mitochondrial DNA replication and maintenance
and is required for cellular and mitochondrial viability.24,25
Associated with the decreased expression of PGC-1α, SuHxRVD tissue had a decreased expression of TFAM (Figure 3A).
Because reduced TFAM mRNA levels are associated with
alterations in mitochondrial biogenesis, we measured the
expression of Top1mt, POGL2, and POLRMT, a set of genes
that encode enzymes required for the replication of mtDNA
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Figure 18. Changes in mitochondrial biology in RV failure tissue. mRNA transcript
levels of genes required for mitochondrial bio- genesis and mitochondrial DNA (mtDNA)
replication and transcription. B, Western blotting of right ventricular (RV) tissue
demonstrates a significantly decreased protein expression of mtDNA-encoded proteins in
SU5416/hypoxia (SuHx)-RV dysfunction. C and D, Electron microscopy demonstrates
abnormal ultrastructure of mitochondria in RV dysfunction. Data are shown in fold
changes±SEM compared with controls; *P<0.01; #P<0.0001. Reproduced with
permission from Gomez-Arroyo J, et al. Metabolic gene remodeling and mitochondrial
dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial
hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–144.
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TFAM mRNA levels is associated with alterations in mitochondrial biogenesis, we
measured the expression of Top1mt, POGL2 and POLRMT, a set of genes that encode
enzymes required for the replication of mtDNA and mitochondrial biogenesis(113, 118).
All three genes were downregulated in dysfunctional (SuHx) RV hypertrophy but not in
PAB-induced RV hypertrophy as illustrated in Figure 18A. To test for decreased mtDNA
transcription, we measured the expression of two mtDNA-encoded proteins proteins:
NADH-ubiquinone oxidoreductase subunit 4L (ND4L) and cytochrome B (CytB). These
two proteins are subunits of the mitochondrial electron-transport chain complexes I and
III respectively. As illustrated in Figure 18B, the relative protein expression of ND4L
and CytB was significantly decreased in SuHx-RVs.
High-power magnification electron microscopy demonstrated that the mitochondrial
ultrastructure in RVD tissue was highly abnormal. In comparison to controls (Figure
18C), mitochondria in SuHx RVs were consistently abnormal in shape and size, and
clumped together in clusters (Figure 18D). Although clustering of mitochondria was also
present in the PAB RVs (Figure 18E, arrow), the overall distribution of mitochondria
was similar to that of control RVs. Upon isolation, RVD tissues exhibited a significantly
decreased amount of mitochondria, as evidenced by mitochondrial yield and by citrate
synthase activity (Figure 19A-B). Isolated mitochondria were studied by respirometry to
evaluate the efficiency of oxidative phosphorylation. RVF-mitochondria demonstrated a
significantly decreased ADP-stimulated (State 3) respiration rate when utilizing
glutamate (Figure 19C) but not when utilizing succinate as electron donors to complex I
and II, respectively.
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results from direct exposure of DNA to ROS.28 Figure 5
shows 8-oxo-G–positive staining in dysfunctional RV tissues,
particularly in the endomyocardial area.

Discussion
RV failure is a common consequence of severe chronic pulmonary hypertension and the most frequent cause of death
in patients with PAH.1 Although RVD plays an important
prognostic role in patients with PAH,29,30 there are relatively
few experimental data shedding light on the mechanisms of
chronic RVD and failure.31,32 Although it has been proposed
that RVD is associated with metabolic gene remodeling,8 a
comprehensive metabolic gene profile of the failing right ventricle is still lacking.
Here we demonstrate that dysfunctional RV hypertrophy,
in rats and patients with PAH, exhibits a significant reduction
in the expression of PGC-1α and its corresponding nuclear
receptors (PPAR-α and ERR-α). Interestingly, the change in
PGC-1α expression seems to be largely independent of the
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Figure 19: A, Amount of mitochondrial protein per 100 mg of right ventricular (RV)
tissue. SU5416/hypoxia (SuHx) and pulmonary artery banding (PAB) RV tis- sues
demonstrate significantly decreased mitochondrial yield when compared with control RV
tissue. B, Whole tissue citrate synthase activity assay demonstrates that SuHx has a
reduced oxidative capacity when compared with control RV. C, State 3 respiration with
complex I substrate (gluta- mate) is significantly decreased in SuHx RV dysfunction
when compared with control or PAB RV tissues. The lines in the box- and-whiskers plots
illustrate the median, whereas the + sign illustrates the mean. *P<0.01; #P<0.0001.
Reproduced with permission from the published from Gomez-Arroyo J, et al. Metabolic
gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy
secondary to pulmonary arterial hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–
144.
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Since mitochondrial dysfunction could contribute to the generation of reactive oxygen
species (ROS), we measured the levels of 8-isoprostane (8-isoProstaglandin F2α) in RVD
tissues. 8-Isoprostane has been proposed as a marker of antioxidant deficiency and
enhanced oxidative stress(151). Analysis from LC tandem mass spectrometry of SuHx
RV tissue demonstrated no change in the amount of 8-isoprostane in comparison to
controls (Figure 20A) but increased levels in the lungs (Figure 20B). However, whereas
the amount of ROS generated might have not been sufficient to cause significant lipid
peroxidation in whole RV tissues, ROS could still induce damage. mtDNA is particularly
susceptible to ROS-induced damage(207) and a common marker of mtDNA damage is
the formation of 7,8-dihydro-8-oxoguanine (8-oxoG), a mutagenic base byproduct that
results from direct exposure of DNA to ROS(18). Figure 21 shows that 8-oxo-G positive
staining in dysfunctional RV tissues, particularly in the endomyocardial area.

	
  

112	
  

Figure 20
Supplemental Figure 3!

B!

A!

40

2.0

8-iso-PGF2-α
(ng/mg weight)

8-iso-PGF2-α
(ng/mg weight)

2.5

1.5
1.0
0.5
0.0

Control

30

20

10

0

SuHx

Right Ventricle Tissue

Control

SuHx

Whole lung tissue

Supplemental Figure 3. LC-tandem mass spectrometric measurement of 8-iso-

Figure 20. LC-tandem mass spectrometric measurement of 8-iso- PGF-2α (8-

PGF-2α (8-isoprostane) in the RV (A) and lung (B) tissue of SuHx rats. N= 4 rats per

isoprostane) in the RV (A) and lung (B) tissue of SuHx rats. N= 4 rats per group. There
group. There were no statistically significant differences between groups.

were no statistically significant differences between groups. Reproduced with permission
from Gomez-Arroyo J, et al. Metabolic gene remodeling and mitochondrial dysfunction
in failing right ventricularLegends
hypertrophy
secondary to pulmonary
for Supplemental
Video arterial hypertension.
Circ Heart Fail. 2013 Jan 1;6(1):136–144.
Supplemental Video 1. This video clip was obtained while performing an
echocardiogram of a rat exposed to SU5416/hypoxia (RVD model). The clip
illustrates the degree of RV dysfunction. Note the significant dilatation of the RV, the
paradoxical septal movement and the important restriction of the left ventricle during
systole and diastole.
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that RVD is associated with metabolic gene remodeling,8 a
comprehensive metabolic gene profile of the failing right ventricle is still lacking.
Here we demonstrate that dysfunctional RV hypertrophy,
in rats and patients with PAH, exhibits a significant reduction
in the
Figure
21.expression of PGC-1α and its corresponding nuclear
receptors (PPAR-α and ERR-α). Interestingly, the change in
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Figure 21. Immunofluorescence shows increased 7,8-dihydro-8-oxoguanine (green) in
right ventricular dysfunction (RVD) tissue vs SU5416/hypoxia (SuHx)-RVD.
Reproduced with permission from Gomez-Arroyo J, et al. Metabolic gene remodeling
and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to
pulmonary arterial hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–144.
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6.3 Discussion
Right ventricular failure is a common consequence of severe chronic pulmonary
hypertension and the most frequent cause of death in patients with PAH(197). Although
RV dysfunction plays a important prognostic role in patients with PAH(237, 244), there
are relatively few experimental data shedding light on the mechanisms of chronic RV
dysfunction (RVD) and failure(23, 246). Whereas it has been proposed that RVD is
associated with metabolic gene remodeling(231), a comprehensive metabolic gene profile
of the failing RV is still lacking.
Here we demonstrate that dysfunctional RV hypertrophy – in rats and patients with PAH
– exhibit a significant reduction in the expression of PGC-1α and its corresponding
nuclear receptors (PPAR-α and ERR-α). Interestingly, the change in PGC-1α expression
appears to be largely independent of the RV pressure overload and hypertrophy.
Moreover, multiple PGC-1α target genes encoding proteins required for fatty acid
metabolism were significantly decreased in expression in RVD tissues. Particularly, the
expression of genes encoding the acyl-CoA dehydrogenases which are specific for fatty
acid β-oxidation, was significantly decreased in dysfunctional SuHx-RV hypertrophy but
not in adaptive PAB-RV hypertrophy. Conversely, functional PAB-RV hypertrophy was
associated with a high expression of ACADS and ACADVL, the latter being the most
important heart acyl-CoA dehydrogenase for FAO. Altogether the gene and protein
expression data suggest that in RVD, FAO is impaired on multiple levels (Figure 22).
Along with the metabolic gene remodeling, we show evidence for an abnormal
mitochondrial ultrastructure and decreased mitochondrial respiration at the level of
complex I of the electron transport chain. Moreover, RVD is characterized by decreased
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Figure 22.

Figure 22. Schematic representation of the multiple steps affected in fatty acid
metabolism during right ventricular failure (black stars). ETC= Electron transport chain.
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expression of genes encoding proteins required for mitochondrial biogenesis such as
TFAM, Top1mt, POGL2 and POLRMT. RVD also demonstrated a significantly low
mitochondrial yield in comparison to control RVs. Finally we demonstrate that RVD
exhibits high levels of 7,8-dihydro-8-oxoguanine, consistent with ROS-induced DNA
damage.
We decided to focus on central transcriptional regulators such as PGC-1α and its
corresponding nuclear receptors ERR-α and PPAR-α, because multiple gene knockout
studies have illustrated that these proteins play an important role during the functional
bioenergetic adaptation of the heart to pressure overload(67, 237, 244). PGC-1α is
preferentially expressed in tissues with high oxidative capacity and coordinates several
biological processes of mammalian energy metabolism by activating genes involved in
cellular uptake and mitochondrial oxidation of fatty acids(179). Heart tissue obtained
from PGC-1α knockout mice displays a reduced palmitoyl-L-carnitine state 3 respiration,
suggesting reduced FAO, and a reduction in the amount of ATP generated per oxygen
consumed (131). Of equal importance, in the absence of PGC-1α, the expression of
mitochondrial genes in the heart is suppressed, the activities of mitochondrial enzymes
are altered and ATP production is reduced (11). As it has been shown in models of left
heart failure(11, 12, 130), the SuHx model of severe PAH and RVD is characterized by
reduced PGC-1α expression. We consider this reduced expression as a central component
of RV metabolic remodeling. Whereas downregulation of PGC-1α is a feature of
dysfunctional hypertrophy, it remains unclear what drives the downregulation of PGC-1α
expression during RVD. As the SuHx model is characterized by capillary rarefaction(25),
ischemia and hypoxia could potentially drive the metabolic remodeling. However, PGC-
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1α expression is not decreased until RVD occurs. Because PGC-1α expression is an HIFindependent hypoxia-inducible gene(10), it is unlikely that the downregulated expression
of PGC-1α and the associated metabolic remodeling profile would be entirely explained
by hypoxia or by HIF activation. Whereas decreased PGC-1α mRNA expression has
been reported in human left heart failure (203), recent studies using samples of left
ventricles obtained from patients with heart failure have demonstrated a relatively normal
expression of PGC-1α(113). Perhaps these discrepant results may be explained by
different drug treatments of the patients with LV failure.
Whereas impaired glucose oxidation has been well characterized in the monocrotalineinjury model of RVD, changes in fatty acid metabolism are less clear(177). In our study,
the downregulation of PGC-1α, ERR-α, and PPAR-α expression was coupled to a
decreased expression of genes encoding FA transport proteins and FAO, which suggests
to us that FA catabolism in the failing RVs is likely compromised on the levels of
regulation, transport and catabolism. Others have reported that changes in FAO occur in
the monocrotaline-injury model of PH, mainly in CPT-1β expression(33), and few case
reports have shown reduced uptake of radiolabeled fatty acid analogues in the RV of
patients with PAH(121). However, it remains unclear whether the changes in FA
metabolism are beneficial or detrimental in the overall function of the RV. In the left
ventricle, multiple studies have shown that the rate FAO is preserved or increased in
physiological/adaptive hypertrophy, and that FAO decreases during the progression of
heart failure(3). Similarly, we demonstrate a normal/increased expression of ACADM,
ACADS and ACADVL in adaptive PAB-RV hypertrophy. These results are supported by
the data of Fang and Archer, who demonstrated that rats with PAB-RV hypertrophy
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exhibit higher rates of FAO(65). We postulate that along with capillary rarefaction,
fibrosis and ROS-induced damage, mitochondrial metabolic remodeling in RVD is
pathological. It has been reported that FAO inhibition may have a therapeutic
potential(65) however, it will remain to be tested whether further inhibition of FAO is
beneficial in the model of SuHx RVD.
While it has been reported that RVD is associated with mitochondrial
hyperpolarization(152), a comprehensive analysis of mitochondrial respiration in RVD is
still lacking. Here we demonstrate that RVD is associated with significant mitochondrial
dysfunction, reduced mitochondrial yield and reduced overall oxidative capacity.
Surprisingly, although the expression of PGC-1α and TFAM was unchanged in PAB-RV
hypertrophy, mitochondrial yield and citrate synthase activity were similarly decreased in
both SuHx-RVD and PAB-RV hypertrophy. Because PGC-1α regulates mitochondrial
biogenesis, our results would suggest an “uncoupling” between PGC-1α expression and
mitochondrial biogenesis in adaptive PAB-RV hypertrophy. Yet, abnormal mitochondrial
biogenesis can occur in the presence of normal PGC-1 levels(113). We speculate that
preserved PGC-1α and TFAM expression could explain the better preserved
mitochondrial respiration in PAB-RV hypertrophy when compared to SuHx-RVD, as
both proteins play a critical role in mitochondrial function(67, 118).
6.4 Study Limitations and Future Directions
We do not know whether a decrease of in PGC-1α expression is a consequence or a cause
of RVF. Nonetheless, our results show that decreased PGC-1α gene expression is not
explained by a toxic effect of SU5416, hypoxia or RV pressure overload. Several
mechanisms may participate in the downregulation of PGC-1α expression in RVD and
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the associated gene metabolic remodeling. We did not explore whether the metabolic
remodeling-dependent gene and protein expression profile affects enzymatic activity.
6.5 Conclusions
Our data illustrate that right ventricular dysfunction is associated with a complex
multilevel disturbance of fatty acid oxidation and mitochondrial respiration that are not
entirely explained by pressure overload or hypertrophy. We propose that RV metabolic
remodeling is a consequence of decreased PGC-1α expression. To what extent metabolic
remodeling or mitochondrial dysfunction is of functional importance for the development
of RVD remains to be investigated.
6.6 Clinical Perspective
Our experiments demonstrate that in the setting of severe pulmonary arterial
hypertension, load-independent alterations of cardiac energy metabolism and
mitochondrial efficiency are associated with RVD. Because RV failure determines the
outcome in patients with severe PAH, the cellular and molecular mechanisms which
underlie RVF need to be understood for they could be reversible. As we design RVtargeted therapies, the use of metabolic modulators should aim to restore not only
substrate utilization but also mitochondrial function.
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Chapter 7: Pharmacotherapies Tested to Reverse Metabolic Remodeling and
Improve Right Ventricular Failure in the SU5416/hypoxia Model of Severe PAH

Segments of this chapter have been previously published in:

Drake JI, Gomez-Arroyo J, et al. Chronic carvedilol treatment partially reverses the
right ventricular failure transcriptional profile in experimental pulmonary hypertension.
Physiol. Genomics. 2013 Apr 30;
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CHAPTER 7
7.1 Introduction
As it was discussed in Chapter 3, studying the mechanisms that contribute to the
development of right ventricular failure is critical in order to develop new therapeutic
strategies. Although we characterized the transcriptional profile in maladaptive RV
hypertrophy (Chapter 6), we still do not know whether these changes in fatty acid
oxidation are indeed adaptive or maladaptive or whether the use of metabolic modulators
could improve function of the failing RV. Therefore, in this chapter, we sought to:
1) Evaluate whether further blockade of fatty acid oxidation improved function of the failing
right ventricle.
2) Evaluate whether other metabolic modulators that do not affect substrate utilization but
rather mitochondrial biogenesis improved function of the failing right ventricle.
3) Evaluate whether treatment with the adrenergic receptor blocker, carvedilol, modified the
metabolic transcriptional profile observed in maladaptive RV hypertrophy.

7.2 Pharmacotherapies Used
7.2.1 Etomoxir (D-enantiomer) treatment
A group of SuHx animals was treated with the fatty acid oxidation blocker Etomoxir.
Etomoxir was purchased as a D-enantiomer from Sigma-Aldrich (St Louis, MO). It was
dissolved in PBS pH 7.4 (phosphate buffered saline 1x) and administered
intraperitoneally in a standard dose of 7 mg/kg/day (equivalent to 15mg/kg/day of
racemic Etomoxir) (133, 201, 233) for 2 weeks, starting once RV failure was established
(as confirmed by echocardiogram). The D-enantiomer of etomoxir was used because it is
more accurate to quantify and administer when compared to the racemic form.
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7.2.2 Resveratrol treatment
Resveratrol dissolved in with propylene glycol and water 50/50 was orally administered
10mg/kg daily by oral gavage for 4 weeks starting once RV failure was established (as
confirmed by echocardiogram).
7.2.3 Recombinant human TFAM treatment
A recombinant human mitochondrial transcription factor A (rhTFAM) produced and
purified by Gencia Corporation, (Charlottesville, VA), kindly shared by Dr. James
Bennett and collaborators. rhTFAM was stored in 50% sorbitol, and dialyzed against 5%
glycerol in 1x PBS then filtered through 10,000 Amicon ultracentrifugal filter units
(MWCO) right before injection. rhTFAM was administered at a dose of .67mg/kg and
injected intravenously through rat tail vein once per week for 4 weeks.
7.2.4 recombinant human TFAM protein sequence and characteristics
For detailed information about the recombinant protein please refer to Reference (110,
227). Briefly, RhTFAM is a translational fusion protein is composed by an HA epitope
placed after an 11-Arginine protein transduction domain (PTD) which facilitates
cytosolic escape of transduced protein after macropinocytosis(110). rhTFAM includes an
N-terminal protein transduction domain to allow rapid translocation across cell
membranes, followed by an SOD2 mitochondrial localization signal to stimulate uptake
through the TOM-TIM mitochondrial translocases. RhTFAM enters the mitochondrial
compartment of cells rapidly and can also transport mtDNA cargo into mitochondria. The
nucleotide sequence corresponding to PTD-HA-MLS-TFAM is shown below:
[6X-His]-[SUMO3]-[11Arg PTD]–[HA]-[SODMLS]-[MatureTFAM]
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[MGHHHHHHGG]-[MSEEKPKEGVKTENDHINLKVAGQDGSVVQ
FKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLE
MEDEDTIDVFQQQTGG]-[RRRRRRRRRRR]-[GEGDIMGEWGNEIFGAI
AGFLGGE]-[MLSRAVCGTSRQLPPVLGYLGSRQ]-[SSVLASCPKKPVSSY LR
FSKEQLPIFK AQNPDAKTTELIRRIAQRWR ELPDSKKKIYQD
AYRAEWQVYKEEISRFKE QLTPSQIM SLEKEIMD KHLKRKAM TKKKEL
TLLGKPKRPRSAYN VYVAERFQEA KGDSPQEKLK TV KENWKNLS
DSEKELYIQH AKEDETRYHN EMKSWEEQ MIEVG RKD LLRRTIKKQR
KYGAEEC) KGDSPQEKLK TVKENWKNLS DSEKELYIQH AKEDETRYHN
EMKSWEEQ MIEVGRKD LLRRTI KKQR KYGAEEC](110).
7.2.5 Adrenergic Receptor Blockage treatment
Carvedilol treatment has been shown to improve RV function in experimental PAH (27).
One group of SuHx (n=4-6) and one group of MCT (n=4-6) animals were treated with
carvedilol (15mg/kg; Sigma-Aldrich, St Louis, MO) dissolved in 20% DMSO and water
and administered once daily per oral gavage for 4 weeks, starting after RV failure was
confirmed by echocardiogram. Another group of SuHx rats was treated with a β-1
selective adrenergic receptor blocker (metoprolol). Metoprolol was administered in a
dose of 150 mg/kg/day, dissolved in the drinking water. Both carvedilol and metoprolol
doses have been validated previously (27).
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Results and Discussions for Each Pharmacological Approach
7.3 Pharmacological inhibition of fatty acid β-oxidation with Etomoxir does not
improve function nor prevent deterioration of right ventricular function.
To begin to address whether the changes in metabolic substrate utilization in the failing
RVs, described in Chapter 6, were an adaptative or a maladaptative mechanism, we
treated a group of SuHx animals (with established RVF assessed by echocardiogram)
with a standarized dose of etomoxir (133, 201, 233), a potent carnitinepalmitoyltransferase-1 (CPT-1) blocker. CPT-1 catalyses a rate-limiting (133) regulated
step in mitochondrial transport of fatty acids, and failing RVs exhibit a residual
expression of CPT-1 that could be targeted (Figure 17) . Therefore, we reasoned that
pharmacological blockade of this enzyme would further reduce FAO in failing RVs, and
if indeed a reduction in fatty acid oxidation in the setting of RVF were beneficial, we
would expect an improvement in RV function after etomoxir treatment. Statistical
analysis revealed that after 2 weeks of treatment with etomoxir or vehicle, there was a
significant deterioration of RV function over time (p=0.013) but no significant difference
in TAPSE or RV systolic area between vehicle and etomoxir treated groups (Figure 23AB). At the time of post-treatment echocardiogram and cardiac catheterization, etomoxir
treatment did not show any improvement in RV function, nor did it modify pulmonary
hypertension (Figure 23C-H). Importantly, etomoxir treatment did not halt the
deterioration of RV function observed over time in the SuHx model (27, 162).
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Figure 23.
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Figure 23. SuHx rats were treated with Etomoxir or Vehicle at a dose 7 mg/kg/day for 2
weeks after the animals had established RVF as assessed by echocardiogram. Paired Ttest reveals an overall significant deterioration in TAPSE (A) and RV systolic area (B) in
both groups. Short-axis cardiac ultrasound illustrates the RV diastolic area (blue line)
from a normal rat (C), when compared with a SU5416/hypoxia rat treated with vehicle
(D) or treated with etomoxir (E). There was no significant difference in the RV diastolic
area between etomoxir-treated and vehicle-treated groups. Separate group analysis at the
time of sacrifice did not show any significant differences in TAPSE (C) or MPAP (D)
between vehicle-treated versus etomoxir-treated animals. N= 4-8 per group. Data are
shown in mean ± SEM.
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Etomoxir was first described as a metabolic modulator for the treatment of acute heart
failure (133) with the rationale that during experimental myocardial infarction, an
overactive 5' AMP-activated protein kinase (AMPK) would drive excessive FAO, which
in turn would result in greater mitochondrial reactive oxygen species formation (133,
233). In these earlier studies, blockade of FAO by etomoxir resulted in improved
functional capacity of the left ventricle, even in a model of LV chronic pressure-overload
(233). Based on these findings, one would predict that chronic etomoxir treatment would
have a beneficial effect in RV function. Interestingly, SuHx failing RVs treated with
etomoxir did not show improved RV function, etomoxir did not lower the pulmonary
artery pressure or decrease RV hypertrophy. More importantly, etomoxir treatment did
not prevent the progression of RVF which is observed in this model (162). These findings
suggest that inhibition of FAO might not be an effective therapeutic strategy for RVF in
the setting of severe PAH.
Conversely, multiple studies have shown that the rate of fatty acid oxidation is preserved
or increased in physiological/adaptive left ventricular hypertrophy, and that it decreases
during the progression of heart failure (156). In a similar fashion, as shown in Chapter 6,
rats with adaptive RV hypertrophy after pulmonary artery banding have increased rates of
fatty acid oxidation (157). Multiple clinical trials evaluating the role of fatty acid
oxidation blockers have been designed (158), however, none of these metabolic
modulators have become a cornerstone in the treatment of heart failure. Moreover, no
clinical trial has evaluated the role of metabolic modulators for PAH-associated RV
failure. Recently, a clinical trial studying dichloroacetate, a mitochondrial modulator, has
been started but it has not yet been concluded (ClinicalTrials.gov Identifier
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NCT01083524). All together, our data would not support the use of fatty acid oxidation
blockade to treat RV failure.
7.4 Resveratrol treatment does not improve function nor prevent deterioration of
right ventricular function
Resveratrol (trans-3,5,4’-trihydroxystilbene) is a polyphenolic compound and naturally
occurring phytoalexin, has been designated the active agent. Resveratrol is a potent
inducer of sirtuins expression and it has been shown to be cardioprotective during
myocardial infarction in rats through induction of VEGF and HO-1 enhancing
neovascularization(112). Resveratrol can directly stimulate NADH dehydrogenases, and
more specifically mitochondrial complex I activity, therefore increasing mitochondrial
NAD+/NADH ratio(52). The NAD-dependent histone deacetylase sirtuin1 (SIRT1) is a
key regulator of lifespan in lower organisms and mice, and plays an important role in
cardiac energy metabolism. Several studies have shown that SIRT1 has pivotal
cardioprotective roles (153). For instance, it has been reported that upregulation of SIRT1
gene expression inhibits apoptosis, protects against oxidative stress and delays the
progression of aging in the mouse heart (6, 7). Moreover, Hsu et al have demonstrated
that cardiac-specific overexpression of SIRT1 protects from ischemia/reperfusion injury
(99). Furthermore, SIRT1 modulates fatty acid oxidation mainly through deacetylation of
PGC-1α (73) which increases PGC-1α activity and expression (autoregulatory
expression)(36). SIRT1 not only plays a critical role in regulating energy substrate
utilization, but also uniquely regulates angiogenesis signaling.
Activation of SIRT1 by the natural phenol resveratrol has also been shown to improve
health and survival of mice on a high-caloric diet (19). Moreover, synthetic SIRT1
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activators –such as SRT1720 –have been shown to protect from diet-induced metabolic
by predominantly by enhancing FAO (66). SRT1720 another activator of SIRT1
promotes energy expenditure and enhanced expression of PGC-1α and PPAR-α (66). We
initially demonstrated that RV failure tissue is characterized by decreased expression of
SIRT1 protein in both humans and rats RVs (Figure 24A-B). Thus, we hypothesized that
treatment with resveratrol would increase SIRT1 protein levels and induce PGC-1α
expression and improve RV function. Interestingly, four weeks of resveratrol treatment
did not improve nor prevented the progression of RV failure (Figure 24C) and in
contrast, right ventricular systolic pressure was significantly increased (mean RVSP
105±10 mmHg).
Multiple studies have demonstrated the beneficial effects of resveratrol and a group of
investigators has even reported that resveratrol treatment ameliorates the pulmonary
hypertension caused by monocrotaline exposure(46). However, as discussed in Chapter 4,
whether the improvement in RV function in this model was attributed to partial
improvement of pulmonary hypertension (which is rather common in the monocrotalineinjury model) or whether resveratrol has direct beneficial effects on the RV was not
investigated or discussed by the authors. Our results demonstrate that resveratrol
treatment was not sufficient to improve the function of the RV but rather worsened the
disease and increase the pulmonary artery pressure. These results are interesting because
PAH is an angiogenic disease where VEGF plays an important role. As mentioned
previously, resveratrol can induce VEGF expression and therefore contribute to
angiogenesis. However, whether this is the mechanism whereby resveratrol worsened
pulmonary hypertension in the SU5416/hypoxia remains to be investigated.
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Figure 24. Protein levels of SIRT1 are decreased in SUHX rat RV tissue (A) and human
RV tissue (B). Function of the RV ventricle pre and post resveratrol treatment (C).
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7.5 Treatment with rhTFAM induces significant upregulation of rat TFAm and
PGC-1α transcript levels and improves RV longitudinal contractility
The mitochondrial transcription factor A, is an essential component for the maintenance
and replication of mitochondrial DNA(118). Thomas, Bennett and collaborators have
demonstrated that rhTFAM can stimulate mitochondrial biogenesis, and restore ATP
levels in cell models of Parkinson’s disease(227). Furthermore, the have demonstrated
that systemic treatment of young adult mice with rhTFAM stimulates mitochondrial
biogenesis, increases mitochondrial respiration in brain, heart and muscle tissues and
increases brain mitochondrial ATP synthesis while reducing ROS-induced damage to
proteins(227). Therefore, because maladaptive RV hypertrophy in the SU5416/hypoxia
model is characterized by decreased TFAm expression, abnormal mitochondrial
biogenesis and by ROS-induced damage of DNA, we hypothesized that treatment with
rhTFAM would improve the abnormal changes in mitochondrial biology and therefore
improve RV function in the SU5416/hypoxia model of RVF.
Although we had originally plan to treat the animals for 4 weeks, we could not
continue the treatment for more than one week. However, the results were encouraging as
we demonstrated that SU5416/hypoxia animals treated with rhTFAM had an
improvement in TAPSE and, perhaps more importantly, exhibited a significant increase
in rat TFAM and PGC-1α transcript levels (Figure 25). Indeed, our findings are
interesting because this is perhaps the first time a genetically engineered agent
specifically designed to modify mitochondrial biogenesis has been utilized to treat RV
failure. However, we should still evaluate whether rhTFAM improved RVF via induction
of PGC-1α, whether it modified the changes in mitochondrial ultrastructure and function

	
  

133	
  

observed in maladaptive RV hypertrophy (described in Chapter 6) and, perhaps most
importantly, evaluate how is rhTFAM inducing the expression of rat TFAM and PGC-1α
transcript levels.
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Figure 25. Although not significant, treatment with rhTFAM was sufficient to improve
the longitudinal contractility of the RV as assessed by tricuspid annular plane systolic
excursion (TAPSE) and cardiac output (A and B). Furthermore, rhTFAM treatment
significantly induced the gene expression of rat TFAM and PGC-1α, as evaluated by
qPCR.
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7.6 Treatment with the adrenergic receptor blocker carvedilol reverses the
metabolic transcriptional profile and improves mitochondrial respiratory efficiency
We have reported that treatment with the non-selective adrenergic receptor antagonist
carvedilol reverses established RVF in two different rat models of PAH
(SU5416/hypoxia and monocrotaline-induced PAH), and that this improvement in RV
function was associated with reduced hypertrophy and improved capillary density of the
RV myocardium((26)). These changes were partially explained by an effect of carvedilol
in the expression of genes that could be potentially relevant for the adaptive response of
the RV to chronic pressure overload(26). However, the mechanisms by which carvedilol
reverses maladaptive RV hypertrophy remain largely incomplete. Carvedilol has been
shown to have pleiotrophic cardioprotective effects beyond heart-rate control. Indeed, a
spectrum of anti-inflammatory, antioxidant, and anti-apoptotic actions of carvedilol have
been reported in vitro and in vivo(135, 265). Based on microarray analysis, we have
previously reported that RVF, in contrast to functional, compensated RV hypertrophy, is
characterized by a distinct gene expression profile(55). The set of differentially
expressed genes was designated “RVF-prediction set”, and we speculated that these
genes might play a critical role in the transition between adaptive hypertrophy and
failure. Based on a similar approach, Drake and the rest of our group performed an indepth array assessment to show that carvedilol treatment affects the expression of a
number of genes from the RVF prediction set(56). An initial analysis of carvediloltreated RVs showed that the gene expression profile mostly resembled that of the RVF
tissue. However, an analysis beyond the boundaries of the prediction set revealed a small
group of genes that were differentially expressed after carvedilol treatment (Figure 26).
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In particular, we found a strong signal from mitochondrial dysfunction Ingenuity
canonical pathway (Figure 27A). We examined the effect of carvedilol treatment on the
expression of PGC-1α, ERR-α and PPAR-α, and their corresponding target genes and
indeed found that carvedilol treatment restored PGC-1α, ERR-α, PPAR-α gene
expression (Figure 27B-C), whereas the treatment with metoprolol had no effect on
PGC-1α or PPAR-α gene expression. Furthermore, carvedilol treatment increased FAO
genes expression towards control levels (Figure 28A).
Similar to what we did in Chapter 6, we measured respiration of mitochondria isolated
from RV tissue obtained from rats treated with carvedilol. Figure 28B demonstrates that
mitochondria obtained from SuHx-RVs had significantly reduced ADP/O ratio, which
measures mitochondrial respiratory efficiency. A lower ADP/O ratio represents higher
oxygen consumption per unit of ADP provided. Next, because impaired mitochondrial
respiration would be reflected in decreased ATP production, we indirectly assessed
decreased ATP levels by measuring the activation (phosphorylation) of the AMPactivated protein kinase (AMPK). Mammalian AMPK is sensitive to the cellular
AMP/ATP ratio and is activated by metabolic stresses that inhibit ATP production (87).
Figure 28 illustrates that carvedilol treatment improved the mitochondrial ADP/O ratio
and restored the protein levels of phosphorylated AMPK, which suggests that carvedilol
treatment improves mitochondrial function and restores ATP levels.
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Figure 26
CARVEDILOL PARTIALLY REVERSES RVF GENE EXPRESSION PATTERN
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with median centering to identify differentially expressed genes.
Briefly, the SAM algorithm for a two-class comparison is as follows.
First, the relative difference in expression between two sets of samples
is calculated for each gene; this is the observed relative difference. To
calculate the expected relative difference, data labels are permuted
and the relative difference is calculated for each gene. The expected
relative difference for a gene will be the average relative difference
across all permutations. The observed relative difference is plotted
against the expected relative difference. Genes that fall outside of a
threshold value, !, will be called significant. !-Values were chosen to
give an acceptable false discovery rate (FDR) of " 5%. For each
gene, we report the FDR-equivalent P value, the q value as a
percentage. The q value is defined as the minimum FDR of a given
individual test at which a gene may be called significant.
The gene list was clustered by hierarchical clustering methods in
Cluster 3.0 (9) and visualized in Java Tree View (39). Based on
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Figure 26. Cluster for class comparison analysis between SU5416/hypoxia RV (failure)
and SU5416/hypoxia + carvedilol RV microarray data sets. 489 probes were called
significant at an α< 0.001 level and multivariate permutation testing gives a false
discovery rate < 5%. Red represents greater relative expression than reference RNA, and
green represents less relative expression than reference RNA. Reproduced with
permission from the publisher from Drake JI, Gomez-Arroyo JG, et al. Chronic
carvedilol treatment partially reverses the right ventricular failure transcriptional profile
in experimental pulmonary hypertension. Physiol. Genomics. 2013 Apr 30.
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Indeed, carvedilol treatment not only increased PGC-1α gene and protein expression but
also the expression of PGC-1α co-activated nuclear receptors ERR-α and PPAR-α as well
as their corresponding target genes and the fact that metoprolol, a selective β2 blocker,
did not restore PGC-1α gene expression could suggest a β2 or perhaps an α receptordependent response. However, there are other pharmacological differences between
metoprolol and carvedilol. As a G-coupled protein receptor, the adrenergic receptor can
also bind non-classical intracellular proteins such as β-arrestins (53). The β-arrestindependent signaling is largely ligand dependent and, in contrast to metoprolol, carvedilol
is a biased agonist that can transactivate different intracellular pathways (258). However,
whether the effects of carvedilol treatment observed in this study are β-arrestin dependent
remains unclear. Furthermore, it remains to be investigated whether carvedilol reversed
the transcriptional profile by directly affecting PGC-1α expression or whether PGC-1α
transcript levels and mitochondrial function normalized after carvedilol improved the
overall cardiac function. Nevertheless, disregarding whether it is a cause or consequence,
our findings are interesting, because they suggest that there are set of genes that
normalize when RV failure is treated (including the mitochondrial function genes),
suggesting that these genes and/or signaling pathways are indeed critical for the reversal
of RV failure.
Conclusions
The first decade of the 21st century finds the community of PAH trialists and researchers
in a peculiar situation: The available drugs have some impact on patient survival but do
not alter the remodeled lung circulation and in contrast, effective treatments targeting the
lung vessels could have detrimental effects on the failing RV. Because there are
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contrasting priorities within the different cell populations of heart and lungs, the
development of PAH treatments that both reduce pulmonary vascular resistance and
improve RV function is not straightforward. For instance, we demonstrated that although
treatment with resveratrol could have had beneficial effects on the RV, non-selective
effects in other organs, such as the lung, could worsen the disease. Specific support of
RV contractility can perhaps be accomplished directly with carvedilol or modulators of
mitochondrial biology such as rhTFAM, but further investigations are warranted.
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Figure 28: A) Quantitative real- time PCR analysis of the PGC-1α downstream genes
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RVs (*P <0.01). ). Reproduced with permission from the publisher from Drake JI,
Gomez-Arroyo JG, et al. Chronic carvedilol treatment partially reverses the right
ventricular failure transcriptional profile in experimental pulmonary hypertension.
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8. SUMMARY OF THE DISSERTATION AND FUTURE DIRECTIONS

As mentioned throughout the dissertation, pulmonary arterial hypertension is a complex
disease. However, the essence of the chapters of these thesis could be summarized in a
few bullet points for any clinician or investigator interested in the study of PAH and the
associated right ventricular failure:

1. Whereas the recent years have seen a dramatic increase in the number of
publications regarding new pathobiological hypotheses, mechanistic studies, preclinical (experimental) trials and clinical studies evaluating biomarkers, mortality
predictors and pharmacotherapies, PAH continues to be an incurable disease.
Moreover, although multiple clinical trials and registries have demonstrated a
shift in survival curves, the overall patient survival in the “modern era of targeted
pharmacotherapies” remains incredibly low and the survival of “incident” PAH
patients appears to be similar to that of the idiopathic PAH patients enrolled in the
1981-1991 NIH registry.
2. Patients with PAH (almost invariably) die from right ventricular failure.
Therefore, characterizing and dissecting the mechanisms that underlie the
transition between adaptive and maladaptive RV hypertrophy is critical for the
development of new treatments. Current (and newly proposed) pharmacotherapies
face a critical paradox: While the remodelled lung circulation in PAH is
characterized by angiogenesis, apoptosis-resistance and cell proliferation, the
failing RV suffers from ischemia, capillary rarefaction and cardiomyocyte
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apoptosis, conditions that could be worsened by pharmacotherapy targeting the
pulmonary vascular remodelling.
3.

Current animal models of PAH are not perfect; however, far from being
exclusive the animal models of chronic RV pressure-overload are complementary
depending on what aspect of the disease the researcher is trying to reproduce.

4. Pressure overload might not be sufficient to drive the stressed right ventricle into
failure. Although our study of patients with Eisenmenger syndrome does not
provide a mechanism to explain the adaptation to pulmonary hypertension in
these patients, it generates multiple hypotheses. Furthermore, the analyses of
animal models of adaptive RV hypertrophy in the pulmonary artery banding rats
suggest that load (pressure)-independent mechanisms contribute to the
development of right ventricular failure.
5. Along with cardiomyocyte apoptosis, cardiac fibrosis, capillary rarefaction, right
ventricular failure is characterized by load-independent, multilevel impairment of
fatty acid oxidation and mitochondrial dysfunction. Whereas downregulation of
PGC-1α could be responsible for the metabolic remodelling that we described in
maladaptive right ventricular hypertrophy, further mechanistic studies are
warranted. Contrary to what has been described for animal and human studies of
left heart failure, we postulate that decreased fatty acid oxidation is secondary to a
broader context of abnormal mitochondrial biology. Hence, metabolic modulators
should focus on restoring the balance between mitochondrial biogenesis and
turnover (mitophagy).
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6. We cannot definitely conclude whether metabolic remodelling is a cause or
consequence of right ventricular failure. However, the gene expression studies
from rats treated with carvedilol, together with the metabolic transcriptional
profile from animals with adaptive right ventricular hypertrophy after pulmonary
artery banding, suggest that restoring fatty acids as the preferential substrate for
the heart is indeed associated with compensated right ventricular function.

As predicted many questions remain, but perhaps the most important question that could
be derived from our research work is: Can prevention of right ventricular dysfunction
prolong life? The results presented in this dissertation suggests that there are indeed
mechanisms of RV failure that can be targeted with the goal to preserve RV function in
the setting of severe PAH.

-------------------------------------------------------

✄
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